Endocrine gland neoplasm
MONDO:0002082A benign or malignant neoplasm arising from the epithelial cells of an endocrine organ. Representative examples include pituitary gland adenoma, pituitary gland carcinoma, thyroid gland carcinoma, carcinoid tumor, and neuroendocrine carcinoma.
Also known as: endocrine gland neoplasm (disease), endocrine gland tumor, endocrine gland tumour, endocrine neoplasm, endocrine system neoplasm, endocrine system tumor, endocrine system tumour, endocrine tumor
4608 clinical trials for this condition and its sub-types, 8 tagged with Endocrine gland neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Endocrine gland neoplasm
-
Malignant endocrine neoplasm 17 trials · 2,932 incl. sub-types
16 sub-types
- Liver cancer 255 trials · 1,708 incl. sub-types Sub-types →
- Neuroendocrine carcinoma 106 trials · 744 incl. sub-types Sub-types →
- Thyroid cancer 166 trials · 328 incl. sub-types Sub-types →
- Thymus cancer 10 trials · 225 incl. sub-types Sub-types →
- Adrenal gland cancer 16 trials · 62 incl. sub-types Sub-types →
- Pineal gland cancer 0 trials · 19 incl. sub-types Sub-types →
- Malignant tumor of parathyroid gland 2 trials · 6 incl. sub-types Sub-types →
- Maligant granulosa cell tumor of ovary 5 trials
- Pituitary cancer 2 trials · 4 incl. sub-types Sub-types →
- Ovarian neuroendocrine neoplasm 0 trials · 2 incl. sub-types Sub-types →
- High-grade neuroendocrine carcinoma of the corpus uteri 0 trials
- Low-grade neuroendocrine tumor of the corpus uteri 0 trials
- Malignant carotid body paraganglioma 0 trials
- Malignant jugulotympanic paraganglioma 0 trials
- Pheochromocytoma/paraganglioma syndrome 2 0 trials
- Pheochromocytoma/paraganglioma syndrome 5 0 trials
-
Liver and intrahepatic bile duct neoplasm 78 trials · 1,752 incl. sub-types
17 sub-types
- Liver cancer 255 trials · 1,708 incl. sub-types Sub-types →
- Biliary tract neoplasm 31 trials · 627 incl. sub-types Sub-types →
- Liver hemangioma 6 trials Sub-types →
- Undifferentiated embryonal sarcoma of the liver 6 trials
- Hepatocellular adenoma 2 trials Sub-types →
- Fibrohistiocytic inflammatory pseudotumor of the liver 0 trials
- Hepatic angiomyolipoma 0 trials
- Hepatic granuloma 0 trials
- Inflammatory pseudotumor of the liver 0 trials
- Liver adenomatosis 0 trials
- Liver inflammatory myofibroblastic tumor 0 trials
- Liver leiomyoma 0 trials Sub-types →
- Liver lipoma 0 trials Sub-types →
- Liver mesenchymal hamartoma 0 trials
- Liver solitary fibrous tumor 0 trials
- Lymphoplasmacytic inflammatory pseudotumor of the liver 0 trials
- Solitary necrotic nodule of the liver 0 trials
-
Neuroendocrine neoplasm 181 trials · 985 incl. sub-types
14 sub-types
- Neuroendocrine carcinoma 106 trials · 744 incl. sub-types Sub-types →
- Lung neuroendocrine neoplasm 21 trials · 540 incl. sub-types Sub-types →
- Digestive system neuroendocrine neoplasm 52 trials · 167 incl. sub-types Sub-types →
- Paraganglioma 53 trials · 57 incl. sub-types Sub-types →
- Carcinoid tumor 33 trials · 47 incl. sub-types Sub-types →
- Prostate neuroendocrine neoplasm 20 trials · 25 incl. sub-types Sub-types →
- Hereditary pheochromocytoma-paraganglioma 6 trials Sub-types →
- Thymic neuroendocrine tumor 3 trials · 6 incl. sub-types Sub-types →
- Bronchial endocrine tumor 4 trials
- Ovarian neuroendocrine neoplasm 0 trials · 2 incl. sub-types Sub-types →
- Breast neuroendocrine neoplasm 0 trials Sub-types →
- Laryngeal neuroendocrine neoplasm 0 trials Sub-types →
- Middle ear neuroendocrine tumor 0 trials Sub-types →
- Uterine corpus neuroendocrine neoplasm 0 trials Sub-types →
-
Thyroid tumor 36 trials · 366 incl. sub-types
5 sub-types
- Thyroid cancer 166 trials · 328 incl. sub-types Sub-types →
- Benign thyroid gland neoplasm 21 trials · 26 incl. sub-types Sub-types →
- TSH producing pituitary tumor 0 trials · 2 incl. sub-types Sub-types →
- Familial thyroglossal duct cyst 2 trials
- Thyroid hyalinizing trabecular adenoma 0 trials
-
Thymus neoplasm 5 trials · 240 incl. sub-types
4 sub-types
- Thymus cancer 10 trials · 225 incl. sub-types Sub-types →
- Thymic epithelial neoplasm 14 trials · 56 incl. sub-types Sub-types →
- Thymic neuroendocrine tumor 3 trials · 6 incl. sub-types Sub-types →
- Benign neoplasm of thymus 0 trials Sub-types →
-
Adrenal gland neoplasm 13 trials · 151 incl. sub-types
8 sub-types
- Adrenal cortex neoplasm 11 trials · 63 incl. sub-types Sub-types →
- Adrenal gland cancer 16 trials · 62 incl. sub-types Sub-types →
- Multiple endocrine neoplasia type 1 34 trials
- Cushing disease due to pituitary adenoma 23 trials
- Benign neoplasm of adrenal gland 0 trials · 19 incl. sub-types Sub-types →
- Pheochromocytoma-paraganglioma 18 trials
- Adrenal medulla neoplasm 0 trials · 16 incl. sub-types Sub-types →
- Pituitary dermoid and epidermoid cysts 0 trials
-
Pituitary tumor 23 trials · 83 incl. sub-types
9 sub-types
- Pituitary gland adenoma 34 trials · 67 incl. sub-types Sub-types →
- Functioning pituitary gland neoplasm 0 trials · 24 incl. sub-types Sub-types →
- Prolactin producing pituitary tumor 2 trials · 11 incl. sub-types Sub-types →
- Non-functioning pituitary gland neoplasm 0 trials · 9 incl. sub-types Sub-types →
- Growth hormone-producing pituitary gland neoplasm 0 trials · 5 incl. sub-types Sub-types →
- Pituitary cancer 2 trials · 4 incl. sub-types Sub-types →
- ACTH-producing pituitary gland neoplasm 1 trial Sub-types →
- Benign neoplasm of pituitary gland 0 trials
- Posterior pituitary gland neoplasm 0 trials Sub-types →
-
Benign endocrine neoplasm 0 trials · 60 incl. sub-types
14 sub-types
- Benign thyroid gland neoplasm 21 trials · 26 incl. sub-types Sub-types →
- Benign neoplasm of adrenal gland 0 trials · 19 incl. sub-types Sub-types →
- Benign neoplasm of parathyroid gland 0 trials · 6 incl. sub-types Sub-types →
- Liver hemangioma 6 trials Sub-types →
- Hepatocellular adenoma 2 trials Sub-types →
- Pineocytoma 1 trial
- MAX-related tumor predisposition 0 trials
- TMEM127-related tumor predisposition 0 trials
- Benign carotid body paraganglioma 0 trials
- Benign neoplasm of pituitary gland 0 trials
- Benign neoplasm of thymus 0 trials Sub-types →
- Bile duct papillary neoplasm 0 trials Sub-types →
- Liver leiomyoma 0 trials Sub-types →
- Liver lipoma 0 trials Sub-types →
-
Tumor of parathyroid gland 3 trials · 46 incl. sub-types
3 sub-types
- Familial primary hyperparathyroidism 1 trial · 35 incl. sub-types Sub-types →
- Benign neoplasm of parathyroid gland 0 trials · 6 incl. sub-types Sub-types →
- Malignant tumor of parathyroid gland 2 trials · 6 incl. sub-types Sub-types →
-
Functioning endocrine neoplasm 0 trials · 38 incl. sub-types
2 sub-types
- Functioning pituitary gland neoplasm 0 trials · 24 incl. sub-types Sub-types →
- Functional pancreatic neuroendocrine tumor 1 trial · 14 incl. sub-types Sub-types →
-
Pineal body neoplasm 4 trials · 22 incl. sub-types
5 sub-types
- Pineal gland cancer 0 trials · 19 incl. sub-types Sub-types →
- Pineal parenchymal cell neoplasm 0 trials · 1 incl. sub-types Sub-types →
- Pineal region teratoma 0 trials · 1 incl. sub-types Sub-types →
- Papillary tumor of the pineal region 0 trials
- Pineal region meningioma 0 trials
-
Non-functioning endocrine neoplasm 0 trials · 16 incl. sub-types
3 sub-types
- Non-functioning pituitary gland neoplasm 0 trials · 9 incl. sub-types Sub-types →
- Non-functional pancreatic neuroendocrine tumor 4 trials Sub-types →
- Non-functioning adrenal cortex adenoma 3 trials
-
Granulosa cell tumor 2 trials · 6 incl. sub-types
2 sub-types
- Ovarian granulosa cell tumor 2 trials · 5 incl. sub-types Sub-types →
- Testicular granulosa cell tumor 0 trials Sub-types →
-
Familial tumoral calcinosis 1 trial
5 sub-types
- Familial hyperphosphatemic tumoral calcinosis/hyperphosphatemic hyperostosis syndrome 0 trials
- Normophosphatemic familial tumoral calcinosis 0 trials
- Tumoral calcinosis, hyperphosphatemic, familial, 1 0 trials
- Tumoral calcinosis, hyperphosphatemic, familial, 2 0 trials
- Tumoral calcinosis, hyperphosphatemic, familial, 3 0 trials
Most studied deeper sub-types
Showing the 400 most recently updated of 758 trials in this tab.
-
Can a custom vaccine train the body to fight liver cancer?
Cure CompletedThis phase 1 trial tests whether a personalized vaccine made from a patient's own immune cells can safely boost the body's defenses against liver cancer. People with early-stage hepatocellular carcinoma receive either microwave ablation alone or ablation followed by seven doses o…
Phase 1 • Sponsor: Chinese PLA General Hospital • Aim: Cure
Last updated Aug 29, 2026 00:00 UTC
-
Can a cancer vaccine train the body to fight advanced tumors?
Cure CompletedThis phase 1 trial is testing an experimental therapeutic cancer vaccine called AST-021p in people with advanced solid tumors that no longer respond to standard treatments. The goal is to see if the vaccine is safe and can trigger an immune response against the cancer. Participan…
Phase 1 • Sponsor: Aston Sci. Inc. • Aim: Cure
Last updated Jul 24, 2026 00:00 UTC
-
New hope for tough lung cancer: LAGOON trial tests powerful drug combo
Disease control CompletedThis study tested two new treatments for people with small cell lung cancer that came back after initial chemotherapy. The experimental drugs, lurbinectedin alone or with irinotecan, were compared to standard treatments (topotecan or irinotecan). The goal was to see if the new op…
Phase 3 • Sponsor: PharmaMar • Aim: Disease control
Last updated Sep 21, 2026 16:00 UTC
-
Second try: pumping chemo straight into the liver for tumors that outsmarted standard treatment
Disease control CompletedResearchers are testing whether delivering chemotherapy directly into the liver through a catheter in the hepatic artery can help people with biliary tract cancer or colorectal cancer that has spread to the liver and stopped responding to standard intravenous chemotherapy. The st…
Sponsor: West China Hospital • Aim: Disease control
Last updated Sep 21, 2026 16:00 UTC
-
Experimental drug boosts Cancer-Killing cells in lymphoma trial
Disease control CompletedThis early-phase trial tests whether adding an experimental drug called NKTR-255 to standard CAR-T cell therapy can improve outcomes for people with large B-cell lymphoma that has returned or not responded to treatment. The study involves 27 adults and focuses on safety and how w…
Phase 1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Sep 21, 2026 16:00 UTC
-
Experimental antibody takes on tough bile duct cancers
Disease control CompletedThis phase 2 trial tests an experimental drug called XmAb20717 in 27 adults with advanced biliary tract cancers (bile duct or gallbladder cancer) that worsened after standard chemotherapy. The drug is a bispecific antibody designed to activate the immune system against cancer by …
Phase 2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Sep 21, 2026 16:00 UTC
-
Can an experimental pill boost cancer immunotherapy? early trial puts HG146 to the test
Disease control CompletedResearchers are running a Phase I trial of HG146, an experimental oral drug, in adults with advanced solid tumors or lymphoma that have worsened despite standard treatments. The study first tests HG146 alone to find a safe dose, then tests it combined with a PD-(L)1 antibody, a t…
Phase 1 • Sponsor: HitGen Inc. • Aim: Disease control
Last updated Sep 21, 2026 16:00 UTC
-
New injection aims to shrink skin tumors before surgery
Disease control CompletedThis early-stage trial tests a drug called PH-762, injected directly into skin tumors, for people with squamous cell carcinoma, melanoma, or Merkel cell carcinoma. Participants receive four weekly injections into one tumor, then have it surgically removed about two weeks later. T…
Phase 1 • Sponsor: Phio Pharmaceuticals Inc. • Aim: Disease control
Last updated Sep 21, 2026 16:00 UTC
-
Double immunotherapy attack shows promise in tough lung cancer
Disease control CompletedThis Phase 3 study tests whether adding tiragolumab (an experimental immunotherapy) to the standard combination of atezolizumab plus chemotherapy can help people with untreated, widespread small cell lung cancer live longer without their disease worsening. About 123 participants …
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can an oral drug slow a rare thymus cancer?
Disease control CompletedResearchers are testing whether lucitanib, an oral drug, can slow the growth of advanced thymic carcinoma that has worsened after at least one round of chemotherapy. The trial enrolls adults with recurrent or metastatic thymic carcinoma. In one part, participants receive lucitani…
Phase 2 • Sponsor: Haihe Biopharma Co., Ltd. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Targeted pill shows promise for rare genetic tumor types
Disease control CompletedThis phase 2 study tested the drug erdafitinib in 316 adults and children with advanced solid tumors that have specific FGFR gene mutations or fusions. The main goal was to see if the drug could shrink tumors. Participants took erdafitinib tablets daily. The study is now complete…
Phase 2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Experimental drug TdCyd aims to reactivate Tumor-Fighting genes in advanced cancer
Disease control CompletedThis early-phase trial tested a new drug called TdCyd in 27 adults with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to turn back on genes that may slow tumor growth. The main goal was to find a safe dose and check for side effect…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug combo aims to boost cancer treatment
Disease control CompletedThis early-phase trial tested whether adding nilotinib (a pill) to paclitaxel (a chemotherapy) is safe and tolerable for people with advanced solid tumors that no longer respond to standard treatments. The study included 47 adults and children aged 12 and older. Researchers aimed…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug combo aims to shrink tough head and neck tumors
Disease control CompletedThis study tests a mix of antibodies that help the immune system fight cancer, block tumor growth signals, and cut off the tumor's blood supply. It is for adults with head and neck cancer that did not respond to prior treatment or has no standard options. Participants receive inf…
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Double attack on liver tumors: radiotherapy plus chemoembolization
Disease control CompletedResearchers test whether adding high-dose radiotherapy to standard chemoembolization slows tumor growth better than chemoembolization alone in adults with hepatocellular carcinoma. Participants have liver tumors up to 9 cm that cannot be removed by surgery or treated with percuta…
Phase 2 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Radioactive antibody combo targets thyroid cancer
Disease control CompletedResearchers are testing a two-step radioimmunotherapy for people with medullary thyroid cancer that has come back. Participants receive a bispecific antibody followed by a radioactive peptide. The goal is to see if this targeted radiation can shrink tumors and how safe it is.
Phase 2 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New combo immunotherapy drug enters human trials for 18 cancers
Disease control CompletedThis early-phase trial tests a new drug called AI-061, which combines two immune-boosting antibodies (anti-PD-1 and anti-CTLA-4) into one treatment. The study will enroll 18 adults with advanced solid tumors that have spread or cannot be removed. The main goals are to find a safe…
Phase 1 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Higher radiation dose vs standard: which fights small cell lung cancer better?
Disease control CompletedResearchers are comparing two doses of chest radiation therapy, 45 Gy and 70 Gy, in people with limited-stage small cell lung cancer. All participants also receive chemotherapy with cisplatin or carboplatin plus etoposide. The trial measures overall survival to see whether the hi…
Phase 3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug combo takes on tough cancers in early trial
Disease control CompletedThis early-phase trial tested a new drug called vilastobart, alone or with another drug (atezolizumab), in 125 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. Researchers also looke…
Phase 1/2 • Sponsor: Xilio Development, Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Experimental drug targets EGFR-Positive bile duct cancer after standard treatment fails
Disease control CompletedResearchers are testing an experimental drug called MRG003 in adults with biliary tract cancer that is EGFR-positive and cannot be removed by surgery or has spread. The trial enrolls people whose cancer worsened after at least one standard treatment. Everyone receives MRG003 by i…
Phase 2 • Sponsor: Lepu Biopharma Co., Ltd. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Statin drug tested to stop liver cancer in cirrhosis patients
Disease control CompletedThis phase 2 trial tests whether simvastatin, a widely used cholesterol-lowering drug, can prevent liver cancer in 52 adults with liver cirrhosis. Participants take simvastatin and are monitored with blood tests and imaging to see if cancer-related markers change. The goal is to …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can cutting arginine from the diet starve solid tumors?
Disease control CompletedThis phase 1 trial is testing whether a diet that severely limits arginine—an amino acid some tumors depend on—is safe and might help control solid tumors. About 25 adults with solid tumors will follow a specially designed low-arginine liquid diet for two 3-week cycles while cont…
Phase 1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
A shot to skip the misery of thyroid hormone withdrawal before cancer treatment?
Disease control CompletedThis phase 3 trial tests whether giving recombinant human thyrotropin (rhTSH) injections before radioactive iodine can effectively destroy leftover thyroid tissue after surgery for differentiated thyroid cancer. Normally, patients must stop thyroid hormone medication to raise TSH…
Phase 3 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New drug SG1827 enters first human tests for Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tests a new drug, SG1827, in people with advanced solid tumors that have stopped responding to standard treatments or have no standard therapy available. The main goals are to check the drug's safety, find the best dose, and get a first look at whether it c…
Phase 1 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Boosting thyroid cancer therapy: does rhTSH make radioactive iodine more effective?
Disease control CompletedThis phase 2 trial tests whether giving recombinant human thyroid stimulating hormone (rhTSH) before radioactive iodine can improve the destruction of leftover thyroid tissue after surgery in people with differentiated thyroid cancer. Participants receive either rhTSH injections …
Phase 2 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
A smarter way to choose liver cancer treatment? a new model aims to match therapy to the patient.
Disease control CompletedThis study tests a decision model that aims to predict whether a person with unresectable hepatocellular carcinoma, a type of liver cancer, will benefit more from transarterial chemoembolization (TACE) alone or TACE combined with atezolizumab plus bevacizumab. Researchers will de…
Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Fiber fuel: could a High-Fiber diet boost cancer treatment?
Disease control CompletedThis study looks at whether eating a high-fiber diet (over 21 grams per day) can change gut bacteria and improve the immune system's ability to fight solid tumors like colorectal cancer. About 25 adults with solid tumors will follow this diet to see if it is safe and helps with t…
Phase 1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a new antibody help the immune system fight Hard-to-Treat tumors?
Disease control CompletedThis trial tests an experimental drug called SNS-101, which targets a protein called VISTA that may help tumors evade the immune system. Researchers give SNS-101 alone or with another immunotherapy, cemiplimab, to adults with advanced solid tumors that have not responded to stand…
Phase 1/2 • Sponsor: Sensei Biotherapeutics, Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Blueberry powder tested as natural blood pressure aid
Disease control CompletedThis study tests whether eating wild blueberry powder every day can lower blood pressure and improve blood vessel health in middle-aged and older men and postmenopausal women with slightly high blood pressure. Researchers will measure artery function and stiffness over time. The …
Phase 1/2 • Sponsor: Colorado State University • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Drug combo shows promise in Hard-to-Treat cancers
Disease control CompletedThis phase 1 trial tested the combination of dasatinib (a pill) and bevacizumab (an infusion) in 50 adults with advanced solid tumors that no longer respond to standard treatments. The goal was to find the safest dose and see how well the two drugs work together to slow cancer gr…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can an experimental drug shrink advanced solid tumors?
Disease control CompletedThis phase 1 trial tests an experimental drug called MRG003 in people with advanced solid tumors, including colorectal cancer, head and neck squamous cell carcinoma, and nasopharyngeal carcinoma. The study aims to find a safe dose and to see whether the drug can shrink tumors. Pa…
Phase 1 • Sponsor: Lepu Biopharma Co., Ltd. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New pill aims to keep chemo on track for GI cancer patients
Disease control CompletedThis study tests whether avatrombopag, a pill that boosts platelet production, can help people with gastrointestinal cancer who develop low platelets from chemotherapy. About 60 participants will receive either avatrombopag or a placebo. The goal is to see if the drug can raise p…
Phase 2 • Sponsor: Hanny Al-Samkari, MD • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control CompletedThis early-phase study tests an experimental drug called MK-6837, given alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug sh…
Phase 1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New drug combo shows promise in halting advanced cancers
Disease control CompletedThis early-phase trial tested a combination of two drugs, vandetanib and everolimus, in 151 people with advanced or metastatic cancer that had stopped responding to standard treatments. The goal was to find the safest dose and see if the combination could slow or stop cancer grow…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New combo therapy aims to shrink Hard-to-Treat neuroendocrine liver tumors
Disease control CompletedThis phase 2 pilot study tests whether combining the immunotherapy drug pembrolizumab (Keytruda) with liver-directed treatments (like embolization or radiation) or peptide receptor radionuclide therapy (PRRT) can shrink tumors in people with well-differentiated neuroendocrine tum…
Phase 2 • Sponsor: Nicholas Fidelman, MD • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New combo shows promise for tough lung cancer
Disease control CompletedThis phase 2 study tested a combination of two drugs—ivonescimab (AK112) and irinotecan liposome—in 60 people with extensive-stage small-cell lung cancer whose disease had worsened after standard first-line therapy. The goal was to see if the combo could slow cancer growth and sh…
Phase 2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a new chemo combo outsmart small cell lung cancer?
Disease control CompletedThis trial is testing whether a new form of chemotherapy called PLX038 can be safely combined with the PARP inhibitor rucaparib to shrink tumors in people with small cell lung cancer, small cell cancer outside the lungs, or other solid tumors. The study has two parts: first, find…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New combo therapy shows promise in battle against advanced liver cancer
Disease control CompletedThis study tests whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) can help people with advanced liver cancer live longer than current standard treatments. About 732 participants who have not had prior systemic therapy will be randomly assigned to receiv…
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Immunotherapy plus precision radiation shows promise for rare skin cancer
Disease control CompletedThis phase II trial tested whether adding stereotactic body radiation therapy (SBRT) to the immunotherapy drug pembrolizumab (Keytruda) works better than pembrolizumab alone for advanced Merkel cell carcinoma, a rare and aggressive skin cancer. Nine patients with metastatic disea…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can a new drug formulation shrink Hard-to-Treat neuroendocrine tumors?
Disease control CompletedThis phase 2 trial is testing an investigational drug called nab-sirolimus in people with advanced neuroendocrine tumors (NETs) of the gastrointestinal tract, lung, or pancreas. Participants must have had up to two prior lines of therapy (excluding somatostatin analogs) and must …
Phase 2 • Sponsor: Aadi Bioscience, Inc. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New drug shows promise for rare ovarian cancer in early trial
Disease control CompletedThis phase 2 trial tested the drug nirogacestat in 53 people with recurrent ovarian granulosa cell tumors, a rare type of ovarian cancer. The goal was to see if the drug could shrink tumors or slow the disease. Participants took nirogacestat orally, and researchers measured how m…
Phase 2 • Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can immunotherapy extend remission in Limited-Stage lung cancer?
Disease control CompletedThis trial is investigating whether adding two immunotherapy drugs, nivolumab and ipilimumab, after standard chemotherapy and radiation can help people with limited-stage small cell lung cancer. Even though initial treatment often works well, the cancer frequently returns within …
Phase 2 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Could a new drug match the standard for liver cancer treatment?
Disease control CompletedThis trial is testing whether a chemotherapy drug called idarubicin works as well as the standard drug doxorubicin when used in a procedure called transarterial chemoembolization (TACE) for liver cancer. TACE delivers chemotherapy directly to the tumor and blocks its blood supply…
Phase 2 • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New drug candidate CBX-12 tested in patients with Hard-to-Treat cancers
Disease control CompletedThis study tested an experimental drug called CBX-12 in 69 adults with advanced solid tumors (like ovarian, lung, breast, or colon cancer) that had stopped responding to standard therapies. The main goals were to check the drug's safety, find the best dose, and see if it could sh…
Phase 1/2 • Sponsor: Cybrexa Therapeutics • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Can a triple attack shrink untreatable liver tumors?
Disease control CompletedThis trial is testing whether combining a procedure that blocks blood flow to tumors (TACE) with two drugs—sintilimab, which boosts the immune system, and bevacizumab, which cuts off tumor blood supply—can safely and effectively treat liver cancer that cannot be surgically remove…
Phase 1 • Sponsor: Second Affiliated Hospital of Guangzhou Medical University • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Can math make thyroid hormone therapy more precise?
Disease control CompletedThis trial tests a new way to personalize the dose of levothyroxine, a thyroid hormone medication, for people who have had surgery for thyroid cancer. Using mathematical and statistical models, the approach aims to predict the best dose for each individual, potentially reducing s…
Sponsor: Zhejiang Provincial People's Hospital • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New cocktail of drugs aims to tackle tough lung cancer
Disease control CompletedThis phase 2 trial tests whether adding experimental drugs (MK-4830, boserolimab, or lenvatinib) to the standard combination of pembrolizumab and chemotherapy can improve outcomes for people with extensive-stage small cell lung cancer. Participants receive one of these new combin…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a glowing dye help surgeons remove pituitary tumors more completely?
Disease control CompletedThis trial tests whether giving a fluorescent dye called indocyanine green during endoscopic surgery helps surgeons remove non-functioning pituitary macroadenomas more completely. About 34 adults with these tumors will be randomly assigned to receive the dye or not during surgery…
Sponsor: Tomislav Felbabić • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a new oral drug outsmart Radioiodine-Resistant thyroid cancer?
Disease control CompletedThis phase II trial is testing an oral drug called RAD001 (everolimus) in people with advanced thyroid cancer that no longer responds to radioactive iodine treatment. The drug works by blocking a key growth pathway (mTOR) in cancer cells. The study aims to see if RAD001 can slow …
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Experimental COM902 drug shows promise in early cancer trial
Disease control CompletedThis early-phase study tested an experimental drug called COM902, alone or with other drugs, in 94 people with advanced cancers like ovarian, lung, and colon cancer. The main goal was to check safety and find the right dose. Researchers also looked for early signs that the drug m…
Phase 1 • Sponsor: Compugen Ltd • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a black seed extract boost immunotherapy against a rare cancer?
Disease control CompletedThis pilot trial is testing whether adding NP-101, a compound from black seed oil, to two immunotherapy drugs (nivolumab and ipilimumab) can help control advanced or metastatic extra-pulmonary neuroendocrine carcinoma (EP-NECA) that has progressed after initial treatment. About 1…
Phase 1 • Sponsor: Amr Mohamed MD • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a modified herpes virus turn the tide against advanced cancer?
Disease control CompletedThis early-stage trial is testing an investigational therapy called OH2, a modified herpes simplex virus designed to infect and destroy cancer cells while also stimulating the immune system. The study will evaluate OH2 alone or in combination with the immunotherapy drug pembroliz…
Phase 1/2 • Sponsor: Binhui Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a new drug tame advanced solid tumors?
Disease control CompletedThis early-stage trial is testing an experimental drug called AEB1102 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The main goal is to find the highest dose that is safe and to understand the drug's…
Phase 1 • Sponsor: Immedica Pharma AB • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a simple belly press make liver cancer radiation more precise?
Disease control CompletedThis trial is testing a new abdominal compression technique to reduce breathing-related movement of liver tumors during radiation therapy. The study will compare this novel method with current compression devices and traditional thermoplastic masks in 120 adults receiving radiati…
Sponsor: Southern Medical University, China • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Immune drug plus targeted chemo shows promise for liver cancer in early trial
Disease control CompletedThis early-phase study tests whether combining the immune-boosting drug nivolumab with a procedure that delivers chemotherapy directly to liver tumors (called deb-TACE) is safe for people with advanced liver cancer. Twenty participants will receive the combination, and researcher…
Early phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New pill targets tough cancers in early human trial
Disease control CompletedThis early-phase trial is testing an oral drug called ATRN-119 in 132 people with advanced solid tumors that have specific DNA repair mutations. The main goals are to check safety, how the drug moves through the body, and whether it can shrink tumors. Participants must be able to…
Phase 1/2 • Sponsor: Aprea Therapeutics • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New drug SKB410 enters human testing for Hard-to-Treat cancers
Disease control CompletedThis early-stage study tests a new drug called SKB410 in about 54 adults with advanced solid tumors who have no standard treatment options left. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive multiple doses…
Phase 1 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a One-Two punch of heat and drainage tame inoperable bile duct cancer?
Disease control CompletedThis trial is testing a personalized treatment for people with inoperable perihilar cholangiocarcinoma, a type of bile duct cancer. The approach combines radiofrequency ablation — using heat to destroy tumor tissue — with complete drainage of bile ducts, guided by both endoscopy …
Sponsor: Clinical Hospital Colentina • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can an RNAi drug shrink Hard-to-Treat tumors?
Disease control CompletedThis phase 1 trial is testing an experimental drug called STP707 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study aims to find a safe dose and see whether the drug can slow or shrink tumors. Participants receive STP707 b…
Phase 1 • Sponsor: Sirnaomics • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Radioactive drug shows promise against advanced cancers
Disease control CompletedThis study tested a new radioactive drug, 177Lu-NeoB, in 35 adults with advanced solid tumors that have a specific marker (GRPR). The goal was to check safety, find the best dose, and see if it shrinks tumors. It is an early-stage trial, so it focuses on safety and dosing, not a …
Phase 1/2 • Sponsor: Advanced Accelerator Applications • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
A drug used during liver surgery may cut the risk of major complications — a study puts it to the test
Disease control CompletedThis study looks at whether giving a drug called terlipressin continuously during keyhole (laparoscopic) liver surgery can lower the chance of severe complications afterward. Terlipressin helps keep blood pressure stable, which may protect organs during surgery. Researchers will …
Sponsor: First Affiliated Hospital, Sun Yat-Sen University • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Can High-Dose vitamin c boost chemo against pancreatic cancer?
Disease control CompletedThis phase II trial tests whether adding high-dose vitamin C (ascorbate) to standard chemotherapy (gemcitabine and nab-paclitaxel) can help people with metastatic pancreatic cancer live longer. About 40 participants are randomly assigned to receive either standard chemo alone or …
Phase 2 • Sponsor: University of Iowa • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a new infusion drug tame advanced solid tumors?
Disease control CompletedThis early-phase trial is testing an experimental drug called SM3321 in people with advanced solid tumors that have stopped responding to standard treatments. The main goal is to see if the drug is safe and tolerable, and to find the best dose. Participants receive SM3321 as a we…
Phase 1 • Sponsor: Beijing StarMab Biomed Technology Ltd • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
A machine that keeps donor livers alive outside the body — could it transform transplantation?
Disease control CompletedThis trial tests whether a device called VitaSmart, which pumps cold, oxygenated preservation fluid through a donor liver before transplant, can reduce early organ dysfunction and improve survival compared with the usual method of simply storing the liver on ice. About 228 adults…
Sponsor: Bridge to Life Ltd. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can a three-drug cocktail shrink advanced bile-duct tumors?
Disease control CompletedThis phase 2 trial is testing whether combining bevacizumab (a blood-vessel growth blocker) with nab-paclitaxel and an oral chemotherapy called S-1 can shrink tumors in people with advanced biliary tract adenocarcinoma that has worsened after initial treatment. About 32 participa…
Phase 2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Drug combo before and after surgery could boost liver cancer outcomes
Disease control CompletedThis study investigates whether combining two drugs—camrelizumab (an immunotherapy) and apatinib (a targeted therapy)—before and after surgery can improve outcomes for people with liver cancer that can be surgically removed. Participants receive the drug combination before surger…
Phase 2 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Experimental drug JS015 takes first steps against advanced solid tumors
Disease control CompletedThis early-stage trial tests an experimental drug called JS015 in people with advanced solid tumors who have run out of standard treatment options. The main goal is to check the drug's safety, find the best dose, and see how the body processes it. Up to 12 participants will recei…
Phase 1 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Experimental drug SHR-7367 takes first step against advanced cancers
Disease control CompletedThis early-stage trial tests an experimental drug called SHR-7367 in people with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 22 participants will …
Phase 1 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Could conscious sedation replace general anesthesia for gallbladder drainage?
Disease control CompletedThis study tests whether endoscopic ultrasound-guided gallbladder drainage can be safely performed using conscious sedation given by the endoscopist, instead of deep sedation or general anesthesia. The trial enrolls elderly, high-risk patients with acute cholecystitis who are not…
Sponsor: Azienda Unita Sanitaria Locale di Piacenza • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Experimental pill takes on advanced cancers alongside immunotherapy
Disease control CompletedThis early-phase trial tests an experimental oral drug, MK-6598, both by itself and in combination with the immunotherapy pembrolizumab (Keytruda) in adults with advanced or metastatic solid tumors. The main goals are to check safety, find the right dose, and see early signs of t…
Phase 1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Virus hunts liver tumors before chemo strikes
Disease control CompletedThis study tests a cancer-killing virus called JX-594 (Pexa-Vec) in people with advanced liver cancer that cannot be removed by surgery. Participants receive the virus through an IV and then directly into liver tumors, followed by the standard drug sorafenib. The goal is to see i…
Phase 2 • Sponsor: Jennerex Biotherapeutics • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Immunotherapy combo aims to outperform standard care in advanced liver cancer
Disease control CompletedThis phase 3 trial compares a combination of two drugs—toripalimab (an immunotherapy) and bevacizumab (an anti-angiogenic agent)—against the standard drug sorafenib as the first treatment for people with advanced liver cancer that cannot be surgically removed. The study enrolls a…
Phase 3 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Experimental drug combo aims to shrink inoperable liver tumors
Disease control CompletedThis phase II trial is testing whether a new biologic drug called PM8002, when combined with standard chemotherapy (FOLFOX), can shrink tumors in people with advanced liver cancer that cannot be removed by surgery. The study enrolls about 35 adults with inoperable hepatocellular …
Phase 2 • Sponsor: Biotheus Inc. • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Smart sugar sensors may improve recovery from complex pancreatic surgery
Disease control CompletedThis study tests whether using a real-time continuous glucose monitor (RT-CGM) during pancreaticoduodenectomy (a complex surgery) helps keep patients' blood sugar in a safe range and improves recovery. About 246 adults scheduled for this surgery will be randomly assigned to stand…
Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Robotic surgery through the mouth could eliminate neck scars in thyroid cancer patients
Disease control CompletedThis trial compares a new robotic surgery that removes the thyroid through the mouth (transoral vestibular approach) to the standard open surgery with a neck incision. The study includes 430 adults aged 18–65 with papillary thyroid cancer. The goal is to see if the robotic method…
Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Immunotherapy combo aims to shrink advanced liver tumors
Disease control CompletedThis phase 2 trial investigates whether combining toripalimab (an immunotherapy) with bevacizumab (a drug that cuts off tumor blood supply) can safely shrink advanced liver cancer when used as the first treatment. About 50 to 60 adults with intermediate or late-stage liver cancer…
Phase 2 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New drug combo tested for tough breast cancer
Disease control CompletedThis study tested the safety of combining two drugs, alpelisib and fulvestrant, in 40 men and post-menopausal women with a certain type of advanced breast cancer (HR+, HER2-, with a PIK3CA mutation) that had worsened after hormone therapy. The goal was to track side effects. The …
Phase 4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Immunotherapy combo targets rare, aggressive lung cancer
Disease control CompletedThis trial investigates whether adding the immunotherapy drug atezolizumab (Tecentriq) to standard chemotherapy (carboplatin and etoposide) helps people with a rare and aggressive lung cancer called large cell neuroendocrine carcinoma (LCNEC). The study enrolls adults with advanc…
Phase 1 • Sponsor: Oncology Center of Biochemical Education And Research • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Personalized vaccine plus immunotherapy shows promise for tough lung cancer
Disease control CompletedThis study tested whether adding a personalized dendritic cell vaccine to the immunotherapy drug atezolizumab could help people with extensive-stage small cell lung cancer stay stable longer after initial chemotherapy. Twenty participants received standard chemo plus atezolizumab…
Phase 1/2 • Sponsor: Instituto Oncológico Dr Rosell • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Engineered virus takes on liver cancer when standard treatment fails
Disease control CompletedThis trial investigates whether JX-594 (Pexa-Vec), a virus modified to attack cancer cells and boost the immune system, combined with best supportive care, can help people with advanced liver cancer live longer. The study enrolls adults whose liver cancer has progressed or who co…
Phase 2 • Sponsor: Jennerex Biotherapeutics • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New pill takes on tough cancers: first human trial begins
Disease control CompletedThis early-phase study tests a new oral drug called TT125-802 in 50 adults with advanced solid tumors (like lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. It is a fi…
Phase 1 • Sponsor: TOLREMO therapeutics AG • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Double immunotherapy plus liver blockade targets eye cancer that spreads
Disease control CompletedThis trial investigates whether combining two immunotherapy drugs (ipilimumab and nivolumab) with a procedure called immunoembolization can help people whose uveal melanoma has spread to the liver. The drugs help the immune system attack cancer cells, while immunoembolization cut…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Two-Drug combo aims to stall rare gut tumors
Disease control CompletedThis trial tests whether combining two drugs—RAD001 (everolimus) and octreotide depot—can slow tumor growth in people with advanced low-grade neuroendocrine cancer (carcinoid or islet cell tumors) that has spread or cannot be removed surgically. Participants take RAD001 daily by …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Could drug holidays improve thyroid cancer treatment?
Disease control CompletedThis study compares two ways of taking the drug pazopanib for people with advanced differentiated thyroid cancer that no longer responds to radioactive iodine. One group takes pazopanib continuously, while the other takes planned breaks and restarts the drug only if the cancer pr…
Phase 2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Can a website help cancer survivors live healthier? large study tests online lifestyle coaching
Disease control CompletedThis study tests whether a secure website with educational sessions, goal-setting, and tracking tools can help survivors of several cancers (including breast, prostate, colorectal, and others) improve their diet, increase physical activity, and manage weight. Participants are age…
Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Experimental cell therapy takes aim at Hard-to-Treat cancers
Disease control CompletedThis early-stage trial tests an experimental cell therapy called IBR854 in people with advanced solid tumors that cannot be surgically removed or have spread. The main goals are to check the treatment's safety and find the right dose. Participants receive the cells by infusion tw…
Phase 1 • Sponsor: Imbioray (Hangzhou) Biomedicine Co., Ltd. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Double-Barreled chemo attack on bile duct cancer shows promise
Disease control CompletedThis study tests a two-pronged chemotherapy approach for people with intrahepatic cholangiocarcinoma (a type of bile duct cancer) that cannot be removed by surgery. Participants receive chemotherapy directly to the liver through a surgically placed pump, plus standard chemotherap…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New pill takes aim at Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tests an experimental tablet called YZJ-5053 in people with advanced solid tumors who have no standard treatment options left. The main goals are to find a safe dose and check for side effects. Researchers will also look at how the drug moves through the bo…
Phase 1 • Sponsor: Shanghai Haiyan Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Immunotherapy drug durvalumab may be safe for liver cancer patients with active hepatitis b
Disease control CompletedThis study tests whether the immunotherapy drug durvalumab can be safely given to people with advanced liver cancer who also have an active hepatitis B infection. All participants receive an antiviral drug (entecavir) to control the hepatitis B virus. The main goal is to see if d…
Phase 2 • Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New combo therapy aims to stop liver cancer from coming back
Disease control CompletedThis study tests whether adding a targeted drug (Donafenib) and chemotherapy directly into the liver's blood supply can prevent liver cancer from returning after surgery. It includes adults with a single large tumor (≥5 cm) and microscopic blood vessel invasion, who are at high r…
Phase 2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Community strategies show promise in curbing hazardous drinking
Disease control CompletedThis study tests a 5-week community-based program that teaches protective behavioral strategies to reduce alcohol use in men aged 35–44 with hazardous drinking habits in rural Vietnam. Participants learn to set safe drinking limits, choose nonalcoholic drinks, and plan ahead, wit…
Sponsor: Chulalongkorn University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Off-the-Shelf immune cells take on tough lymphoma
Disease control CompletedThis early-stage trial is testing a new treatment called ACE1831 for adults with B-cell lymphoma that has come back or not responded to at least two prior treatments. ACE1831 uses immune cells from healthy donors that are modified to target and kill cancer cells. The study aims t…
Phase 1 • Sponsor: Acepodia Biotech, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Immunotherapy-Targeted therapy combo shows promise for advanced liver cancer
Disease control CompletedThis clinical trial is testing a combination of two drugs—an immunotherapy (pembrolizumab/quavonlimab) and a targeted therapy (lenvatinib)—as a first treatment for people with advanced hepatocellular carcinoma, a type of liver cancer that cannot be removed by surgery. The study a…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
HIV-Fighting cells show promise in lymphoma treatment
Disease control CompletedThis study tested a new approach for people with both HIV and lymphoma. After high-dose chemotherapy and a stem cell transplant, participants received specially grown HIV-fighting immune cells (HST-NEETs). The goal was to see if giving these cells was feasible and if they could r…
Phase 2 • Sponsor: Catherine Bollard • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Immunotherapy duo before liver surgery shows promise against cancer
Disease control CompletedThis trial investigates whether giving two immunotherapy drugs, ipilimumab and nivolumab, before liver surgery can help shrink tumors in people with liver cancer (hepatocellular carcinoma). Participants receive the drugs in the weeks leading up to their planned surgery. The study…
Phase 1/2 • Sponsor: Imperial College London • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug cocktail aims to make inoperable abdominal cancers operable
Disease control CompletedThis phase 2 trial tested a combination of two drugs—paclitaxel (given intravenously and directly into the abdomen) and oral nilotinib—in 21 adults with cancers that had spread to the lining of the abdomen and could not be surgically removed. The goal was to see if the treatment …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug duo shows promise for Hard-to-Treat cancers
Disease control CompletedThis phase 2 study tested a combination of two drugs—olaparib and pembrolizumab—in 333 adults with advanced solid tumors that have specific DNA repair problems (HRR mutations or HRD). The goal was to see if the combo could shrink tumors or slow their growth. Participants had alre…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Lung cancer trial tests two new combo therapies against tough disease
Disease control CompletedThis phase II trial studied 168 people with extensive-stage small cell lung cancer. Researchers added either vismodegib or cixutumumab to standard chemotherapy (cisplatin and etoposide) to see if these combinations worked better than chemo alone. The goal was to slow cancer growt…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Could a PARP inhibitor boost chemo for tough lung cancer?
Disease control CompletedThis study tested whether adding veliparib (a PARP inhibitor) to standard chemotherapy (cisplatin and etoposide) helps people with extensive stage small cell lung cancer or certain other lung cancers that have spread. In the first phase, researchers found the best dose of velipar…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
One-Patient trial tests keytruda for rare ovarian cancer
Disease control CompletedThis study tested the drug pembrolizumab (Keytruda) as a follow-up treatment for one patient with a rare type of ovarian cancer called small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). The goal was to see if the drug could help keep the cancer from coming back. Beca…
Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Cholesterol-Lowering drug aims to stop first heart attacks
Disease control CompletedThis large study tested whether evolocumab (Repatha), a cholesterol-lowering injection, could reduce major cardiovascular events like heart attacks, strokes, or death in over 12,000 adults at high risk but without a prior heart attack or stroke. Participants received either evolo…
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Liver cancer drug combo shows promise in large trial
Disease control CompletedThis study tested whether adding the chemotherapy drug doxorubicin to the targeted therapy sorafenib helps people with advanced liver cancer live longer. Over 350 patients received either sorafenib alone or sorafenib plus doxorubicin. The main goal was to compare overall survival…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Fish oil supplement tested for muscle loss in liver cancer patients
Disease control CompletedThis completed trial tested whether a daily EPA (an omega-3 fatty acid) supplement could help preserve muscle mass and reduce inflammation in 18 people with advanced liver cancer that could not be surgically removed. Participants took either the EPA supplement or a placebo for 12…
Sponsor: Instituto de Investigación Sanitaria Aragón • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New cancer drug CFI-402257 enters first human trial
Disease control CompletedThis Phase 1 trial tested an investigational oral drug called CFI-402257 in 52 people with advanced solid tumors, including breast cancer, that had stopped responding to standard treatments. The main goal was to find a safe dose and check how the drug moves through the body. It w…
Phase 1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New cocktail of drugs shows promise for tough bile duct cancer
Disease control CompletedThis study tested a combination of three drugs—camrelizumab, apatinib, and chemotherapy (gemcitabine plus cisplatin)—in 49 people with advanced biliary tract cancer that could not be removed by surgery. The goal was to see if the combo is safe and how well it shrinks tumors. Resu…
Phase 1/2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New immunotherapy cocktail aims to simplify cancer treatment
Disease control CompletedThis study tested a fixed-dose combination of two immunotherapy drugs, tiragolumab and atezolizumab, given together as a single infusion every three weeks. The trial enrolled 64 people with advanced solid tumors that express a protein called PD-L1. The main goal was to check the …
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo takes on advanced cancers in early trial
Disease control CompletedThis early-phase trial tested an experimental drug called KVA12123, given alone or with the immunotherapy Keytruda, in 40 adults with advanced solid tumors (like lung, breast, or colon cancer) that had stopped responding to standard treatments. The main goals were to check safety…
Phase 1/2 • Sponsor: Kineta Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take on liver cancer in early trial
Disease control CompletedThis early-phase trial tested a new approach for advanced liver cancer that has not responded to standard treatments. Researchers took participants' own immune cells, modified them in a lab to target a protein called AFP found on cancer cells, and infused them back after a short …
Phase 1 • Sponsor: Adaptimmune • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail aims to stop liver cancer recurrence after surgery
Disease control CompletedThis study tested whether a combination of two drugs (atezolizumab and bevacizumab) can prevent liver cancer from returning in people who had surgery or ablation to remove their tumor. About 668 participants at high risk of recurrence were randomly assigned to receive the drug co…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Modified virus injected into tumors shows promise for liver cancer
Disease control CompletedThis phase 2 trial tested a modified virus called JX-594 (Pexa-Vec) in 30 people with liver cancer that could not be surgically removed. The virus was injected directly into the liver tumors to see if it could stop the cancer from growing. Researchers measured how many patients h…
Phase 2 • Sponsor: Jennerex Biotherapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Radiation and immunotherapy combo shows promise in small cancer study
Disease control CompletedThis pilot study tested whether combining high-dose radiation therapy with the immunotherapy drug pembrolizumab (Keytruda) could boost the immune system's ability to fight advanced solid tumors. Twenty-one patients with various advanced cancers received the combination either at …
Phase 1 • Sponsor: James Larner, MD • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for liver cancer patients with cirrhosis? tiny trial tests drug duo
Disease control CompletedThis small, completed phase II study tested the safety of combining two drugs—atezolizumab (an immunotherapy) and bevacizumab (a blood vessel blocker)—in 6 people with advanced liver cancer who also had moderate cirrhosis (Child-Pugh B7 or B8). The goal was to see if this treatme…
Phase 2 • Sponsor: Howard S Hochster • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo tested for tough lung cancer – modest hopes
Disease control CompletedThis study looked at adding sunitinib malate (a drug that blocks tumor blood flow) to standard chemotherapy for people with extensive-stage small cell lung cancer. The trial involved 156 participants and aimed to find the best dose and see if maintenance sunitinib after chemo cou…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo approach before surgery may improve outcomes for massive liver tumors
Disease control CompletedThis study looked at 715 patients with very large liver cancers (over 10 cm) to see if giving a combination of local treatments (like chemo directly into the liver) and body-wide treatments (targeted drugs and immunotherapy) before surgery helps them live longer. Patients were di…
Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New drug duo shows promise for tough cancers
Disease control CompletedThis study tested two experimental drugs (AK104 and AK117) together, sometimes with chemotherapy, in 128 people with advanced solid tumors. The goal was to see if the combination is safe and can shrink tumors. It focused on patients with stomach, esophageal, or other advanced can…
Phase 1/2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Cancer patients get continued access to promising targeted therapy
Disease control CompletedThis study offers ongoing treatment with alectinib or crizotinib to about 200 adults with ALK- or RET-positive cancer who were already benefiting from these drugs in a previous Roche trial. The main goal is to monitor safety and side effects as patients continue therapy after the…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New targeted therapy combo aims to boost remission in Tough-to-Treat lymphoma
Disease control CompletedThis Phase 3 trial tested whether adding the targeted drug polatuzumab vedotin to a standard chemotherapy regimen (R-ICE) helps people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study enrolled 306 adults whose lymphoma had come back or did not respond …
Phase 3 • Sponsor: GWT-TUD GmbH • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Promising drug cocktail targets Hard-to-Treat liver cancer
Disease control CompletedThis study tested a combination of two drugs, cadonilimab and regorafenib, in 36 adults with advanced liver cancer that had worsened after standard treatments. The goal was to see if the combo could slow cancer growth and how safe it was. Results may help develop better options f…
Phase 1/2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New pill shows promise in shrinking Hard-to-Treat breast tumors
Disease control CompletedThis study tested a new oral drug called BGB-43395 in 33 Chinese patients with advanced or metastatic HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. The goal was to find a safe dose and see if it can shrink tumors wh…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Virus therapy takes on liver cancer in major trial
Disease control CompletedThis study tested whether adding a virus-based immunotherapy (Pexa-Vec) to the standard drug sorafenib helps people with advanced liver cancer live longer. About 459 adults with advanced liver cancer who had not received prior treatment took part. The approach uses a modified vir…
Phase 3 • Sponsor: SillaJen, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Experimental vaccine targets Hard-to-Treat cancers in first human test
Disease control CompletedThis early-phase trial tested a new type of vaccine made from a patient's own immune cells (dendritic cells) that are engineered to target a protein called WT1 found in many cancers. Ten people with advanced esophageal, pancreatic, ovarian, or liver cancer received six vaccines o…
Phase 1/2 • Sponsor: University Hospital, Antwerp • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Could a flavonoid combo reverse liver scarring and prevent cancer in hepatitis b?
Disease control CompletedThis completed phase 4 trial tested whether adding SB Flavon (a blend of flavonoids, vitamin C, and L-arginine) to standard Tenofovir therapy can reverse advanced liver scarring (cirrhosis) and prevent liver cancer in 134 people with chronic hepatitis B. The study measured liver …
Phase 4 • Sponsor: Trieu, Nguyen Thi, M.D. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug combo shows promise in shrinking liver tumors before surgery
Disease control CompletedThis study tested a combination of two drugs (atezolizumab and bevacizumab) given before surgery to people with liver cancer. The goal was to see how well the drugs shrink the tumor and how they affect the immune system. 40 participants were enrolled, and researchers also studied…
Phase 2 • Sponsor: Tae Won Kim • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Immunotherapy combo shows promise for tough pituitary tumors
Disease control CompletedThis phase 2 trial tested two immunotherapy drugs, nivolumab and ipilimumab, in 10 patients with aggressive pituitary tumors that worsened after surgery and radiation. The goal was to see if the combination could shrink tumors or slow their growth. Researchers also monitored side…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug cocktail shows promise for tough bile duct cancer
Disease control CompletedThis trial tested a three-drug combination—chemotherapy infused into the liver, an immunotherapy drug (tislelizumab), and a targeted pill (regorafenib)—as a first treatment for 31 people with advanced bile duct cancer that couldn't be removed by surgery. The goal was to see how m…
Phase 2 • Sponsor: The First Affiliated Hospital of Zhengzhou University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Shorter radiation may be as effective for lung cancer
Disease control CompletedThis study tested whether a shorter course of radiation (hypofractionated) given with chemotherapy works as well as the standard longer radiation course for people with limited-stage small cell lung cancer. 860 adults aged 18-70 with early-stage disease took part. The main goal w…
Phase 3 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug XTX202 tested in patients with advanced cancers
Disease control CompletedThis study tested a new drug called XTX202 in 95 people with advanced solid tumors that had not responded to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The trial is now complete.
Phase 1/2 • Sponsor: Xilio Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug cocktail aims to tackle childhood cancers that Won't quit
Disease control CompletedThis early-phase study tested a combination of two drugs, cabozantinib and 13-cis-retinoic acid, in 15 children whose solid tumors had come back or were not responding to standard treatments. The main goal was to find the safest dose and understand side effects. The study did not…
Phase 1 • Sponsor: Peter Zage • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Engineered immune cells take aim at tough childhood cancers
Disease control CompletedThis early-phase trial tested whether a new type of immune cell therapy (CD22 CAR T cells) could be safely made and given to 10 children and young adults whose B-cell leukemia or lymphoma had come back or stopped responding to treatment. The therapy uses the patient's own immune …
Phase 1 • Sponsor: Kara Lynn Davis • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug cocktail may make inoperable liver cancer removable
Disease control CompletedThis study tested a combination of chemotherapy infused into the liver artery plus two drugs (camrelizumab and apatinib) in 21 people with liver cancer that could not be surgically removed. The goal was to shrink the tumors enough to allow surgery. The study is complete, and resu…
Phase 2 • Sponsor: Shandong Cancer Hospital and Institute • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Experimental combo targets Hard-to-Treat GI cancers
Disease control CompletedThis early-phase trial tested two drugs together—pembrolizumab (Keytruda) and XL888—in 47 people with advanced gastrointestinal cancers like colorectal and pancreatic cancer that had spread or could not be removed. The main goal was to find the safest dose and check for side effe…
Phase 1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Immunotherapy cocktail before surgery shows promise against tough cancers
Disease control CompletedThis study tested whether adding an experimental drug (CCR2/5-inhibitor or anti-IL-8) to the immunotherapy nivolumab before and after surgery could help shrink tumors and improve long-term survival in people with non-small cell lung cancer or liver cancer. 48 participants receive…
Phase 2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Virus injection targets liver tumors in early trial
Disease control CompletedThis early-phase study tested a new treatment called JX-594, a modified virus injected directly into liver tumors. The goal was to find the safest dose and see if it could shrink tumors in 14 patients with advanced liver cancer that had not responded to standard treatments. The s…
Phase 1 • Sponsor: Jennerex Biotherapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New radioactive compound shows promise in targeting Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested a new radioactive drug called 177Lu-CTR-FAPI in 12 people with advanced solid tumors (breast cancer, sarcoma, or thyroid cancer) that had spread and no longer responded to standard treatments. The main goals were to see if the drug is safe and how it…
Early phase 1 • Sponsor: Lanzhou University Second Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New combo therapy shows promise in controlling advanced liver cancer
Disease control CompletedThis study tested a combination of Y90 radioembolization (a targeted radiation treatment for the liver) and nivolumab (an immunotherapy drug) in 40 Asian patients with advanced liver cancer that could not be surgically removed. The goal was to see if the combination could shrink …
Phase 2 • Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug duo aims to tackle Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called TJ004309, either alone or combined with another drug called Toripalimab, in 225 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and see early signs of effectiveness. The…
Phase 1/2 • Sponsor: TJ Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug cocktail aims to fight advanced cancers
Disease control CompletedThis early-phase study tested a daily combination of two oral drugs, axitinib and everolimus, in 19 people with advanced solid tumors, particularly kidney cancer. The main goal was to find the safest dose by monitoring side effects in the first month. Researchers also tracked how…
Phase 1 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New combo therapy shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis study tested a combination of two drugs, acalabrutinib and pembrolizumab, in 161 people with various blood cancers such as lymphoma, leukemia, and multiple myeloma. The main goal was to check safety and side effects, while also seeing if the tumors shrank. The approach aims …
Phase 1/2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Radioactive beads show promise for liver tumors in french registry
Disease control CompletedThis completed registry tracked 332 liver cancer patients in France who received SIR-Spheres, tiny radioactive beads injected into the liver's blood supply to target tumors. The goal was to see how this treatment is used in everyday practice and to monitor safety and survival. Re…
Sponsor: Cardiovascular and Interventional Radiological Society of Europe • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for advanced thyroid cancer: drug shows tumor-shrinking promise
Disease control CompletedThis study tested the drug sunitinib (Sutent) in 71 people with advanced thyroid cancer that had spread or could not be removed by surgery. The goal was to see if the drug could shrink tumors when standard treatments like radioactive iodine no longer work. Participants took sunit…
Phase 2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested a new oral drug called HMPL-453 tartrate, either alone or combined with chemotherapy or an immunotherapy (toripalimab), in 190 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see if th…
Phase 1/2 • Sponsor: Hutchison Medipharma Limited • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug shows promise in early trial for advanced cancers
Disease control CompletedThis early-phase study tested a new drug called CCT3833 in 31 adults with advanced solid tumours, including melanoma. The main goal was to find a safe dose and check for side effects. Researchers measured how the drug moves through the body and looked for the best dose to use in …
Phase 1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New cancer drug PM14 enters human testing for advanced tumors
Disease control CompletedThis early-phase trial tested a new drug called PM14 in 126 people with advanced solid tumors that had no standard cure. The main goals were to find a safe dose and check for early signs of tumor shrinkage. The drug was given by IV infusion on different schedules. This is a first…
Phase 1 • Sponsor: PharmaMar • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Could a triple therapy beat back tough liver cancer?
Disease control CompletedThis completed study tested whether adding a liver-directed chemotherapy infusion (HAIC) to standard immunotherapy and anti-angiogenesis drugs improves outcomes for people with advanced liver cancer that has spread into the portal vein. Over 1,600 participants were included. The …
Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New combo therapy shows promise for tough liver cancer cases
Disease control CompletedThis study looked at adding a procedure called TACE (which blocks blood flow to tumors) to a mix of immunotherapy and anti-angiogenesis drugs for people with advanced liver cancer that has invaded major blood vessels. Over 2,600 participants were included to see if the triple com…
Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Yeast vaccine shows promise in stopping Cancer's return
Disease control CompletedThis early-stage study tested a custom-made yeast vaccine designed to train the immune system to recognize and attack leftover cancer cells. Five adults with various cancers (like colorectal, breast, or lung) who had completed initial treatment received the vaccine. The goal was …
Phase 1 • Sponsor: NantBioScience, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug shows promise in early liver cancer trial
Disease control CompletedThis early-phase study tested a drug called itacitinib in 19 adults with advanced liver cancer that had not responded to first-line treatment. The goal was to check the drug's safety and see if it could shrink tumors or slow cancer growth. Itacitinib works by blocking a protein t…
Phase 1 • Sponsor: Imperial College London • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Zapping adrenal tumors could lower blood pressure without surgery
Disease control CompletedThis study tested a procedure called radiofrequency ablation, which uses heat to destroy a small adrenal gland tumor that causes high blood pressure. Researchers wanted to see if it could safely lower blood pressure in 31 patients with primary aldosteronism. The goal was to reduc…
Sponsor: University Hospital, Toulouse • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Lutathera under the microscope: how does it perform in real patients?
Disease control CompletedThis study followed 164 adults with advanced, progressive neuroendocrine tumors of the gut or pancreas who were treated with Lutathera (a radioactive drug) in normal hospital settings. Researchers measured how long patients lived without their cancer getting worse and how many tu…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo attack on lymphoma shows promise in early trial
Disease control CompletedThis early-phase trial tested a three-part treatment for non-Hodgkin lymphoma: freezing tumors (cryoablation), injecting a personalized dendritic cell vaccine made from the patient's own cells, and giving the immunotherapy drug pembrolizumab (Keytruda). The goal was to find the s…
Phase 1/2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for tough thyroid cancers? cabozantinib trial shows promise
Disease control CompletedThis study tested the drug cabozantinib in 41 adults with advanced differentiated thyroid cancer that no longer responds to radioactive iodine treatment. Participants took a 60 mg pill daily until their cancer worsened or side effects became too severe. The main goal was to under…
Phase 2 • Sponsor: Grupo Espanol de Tumores Neuroendocrinos • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New cancer drug HBM1020 tested in tiny early trial
Disease control CompletedThis early-phase study tested a new drug, HBM1020, in 17 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The drug was given by IV every three weeks. Because this is a Phase 1 trial, i…
Phase 1 • Sponsor: Harbour BioMed US, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Radiation may buy time for liver cancer patients before stronger meds needed
Disease control CompletedThis study tested whether giving radiotherapy to liver cancer patients with limited tumor growth (oligo progression) could delay the need for second-line drug therapy. Thirty-six adults with advanced hepatocellular carcinoma received targeted radiation. The goal was to see if thi…
Sponsor: Shandong Cancer Hospital and Institute • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Exergaming and mediterranean diet tested for thyroid cancer recovery
Disease control CompletedThis study looked at whether playing active video games (exergaming) and following a Mediterranean diet could help people who had their thyroid removed due to cancer. 80 adults were split into four groups: one did exergaming, one followed the diet, one did both, and one had no ex…
Sponsor: Nabil Mahmoud Ismail Abdel-Aal • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Experimental drug PRL3-ZUMAB shows promise in Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called PRL3-ZUMAB in 14 people with advanced solid tumors (like stomach or liver cancer) that stopped responding to standard treatments. The drug was given every two weeks to see if it could shrink tumors or stop them from growing. Researchers also lo…
Phase 2 • Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New ALK inhibitor ensartinib tested in first human trial for lung cancer
Disease control CompletedThis study tested a new oral drug called ensartinib (X-396) for the first time in humans. It involved 131 people with advanced solid tumors, including those with ALK-positive non-small cell lung cancer. The goal was to find the safest dose and see if the drug could shrink tumors.…
Phase 1/2 • Sponsor: Xcovery Holdings, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New drug combo shows promise in slowing rare gut tumors
Disease control CompletedThis study tested whether adding the drug axitinib to standard sandostatin LAR therapy could slow tumor growth in 256 people with advanced neuroendocrine tumors (G1-G2) that started outside the pancreas. Participants received either the combination or sandostatin plus a placebo. …
Phase 2/3 • Sponsor: Grupo Espanol de Tumores Neuroendocrinos • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Experimental antibody HH-101 tested in 12 patients with advanced cancers
Disease control CompletedThis early-stage trial tested an experimental drug called HH-101 in 12 people with advanced solid tumors that had not responded to standard treatments. The main goal was to check the drug's safety and find the right dose. Participants received HH-101 as an IV infusion every three…
Phase 1 • Sponsor: Huahui Health • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Triple therapy shows promise for advanced liver cancer
Disease control CompletedThis study tested a triple combination treatment for advanced liver cancer that has spread. It combines a procedure called TACE (which blocks blood flow to the tumor) with immunotherapy drugs (PD-1/PD-L1 inhibitors) and targeted therapies (VEGF-TKI or bevacizumab). The goal is to…
Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Triple therapy shows promise for intermediate liver cancer
Disease control CompletedThis study tested a three-pronged approach for intermediate-stage liver cancer: a procedure that blocks blood flow to the tumor (TACE), immunotherapy drugs that help the immune system fight cancer, and targeted drugs that stop blood vessel growth. Over 900 patients participated. …
Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Immunotherapy drug shows promise in bile duct cancer trial
Disease control CompletedThis Phase 3 trial tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (gemcitabine and cisplatin) helps people with advanced bile duct cancer live longer. The study enrolled 158 Chinese adults with cancer that had spread or could not be removed by…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Experimental combo targets Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a combination of two drugs—177Lu-DOTA-TATE (a radioactive therapy) and olaparib (a PARP inhibitor)—in 18 people with certain cancers like neuroendocrine tumors, thymoma, or mesothelioma that have a specific marker (somatostatin receptor). The goal wa…
Phase 1 • Sponsor: Vastra Gotaland Region • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New Double-Action antibody shows promise against Hard-to-Treat cancers
Disease control CompletedThis phase 2 trial tested an experimental drug called HX009 in 20 adults with advanced solid tumors that had stopped responding to standard treatments. HX009 is a bifunctional antibody designed to block two proteins (CD47 and PD-1) that help tumors hide from the immune system. Th…
Phase 2 • Sponsor: Hangzhou Hanx Biopharmaceuticals, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope: hepatitis c drugs after liver cancer treatment
Disease control CompletedThis study tested whether interferon-free drug combinations can cure hepatitis C in 150 people who had been successfully treated for liver cancer. Participants took pills like sofosbuvir and ribavirin for 12 weeks. The main goal was to see if the virus stayed undetectable 12 week…
Phase 3 • Sponsor: National Hepatology & Tropical Medicine Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New needle combo zaps returning liver tumors after failed chemo
Disease control CompletedThis study tested a special type of radiofrequency ablation using two cooled needles that also release saline to treat liver cancer that came back after chemoembolization. The goal was to see if this technique could better destroy the tumor and prevent it from growing back. One h…
Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
HIV patients with liver failure get new drug combo tested in transplant study
Disease control CompletedThis study looked at how the HIV drug raltegravir works in people with severe liver disease who need a liver transplant. It included 14 HIV-positive adults with end-stage liver failure. Researchers checked how the drug behaves in the body and how it interacts with anti-rejection …
Phase 1/2 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New combo therapy shows promise in tough lung cancer battle
Disease control CompletedThis study tested whether adding a new drug called tiragolumab to standard chemotherapy and immunotherapy helps people with advanced small cell lung cancer live longer without their cancer getting worse. About 490 adults who had not received prior treatment for this stage of canc…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Radioactive oil injection may keep liver cancer at bay
Disease control CompletedThis phase 3 trial tested whether a single injection of radioactive lipiodol (Lipiocis) into the liver artery could prevent hepatocellular carcinoma from coming back after surgery or ablation. The study enrolled 73 adults with cirrhosis and one or two liver tumors that had been s…
Phase 3 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Surgeons test wrapping trick to prevent pancreatic leaks after whipple
Disease control CompletedThis study tested a new way to reconnect the pancreas to the intestine during Whipple surgery for certain cancers. The new method uses a stent and wraps the connection with omentum (fatty tissue) to try to prevent leaks. 48 patients were split into two groups to compare the new t…
Sponsor: Theodor Bilharz Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Double attack on liver cancer: does adding RFA to TACE improve survival?
Disease control CompletedThis phase 3 trial tested whether adding radiofrequency ablation (RFA) to standard transarterial chemoembolization (TACE) improves outcomes for people with intermediate-stage liver cancer. 241 participants with 2-10 liver tumors were randomly assigned to receive either TACE alone…
Phase 3 • Sponsor: Ming Zhao • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New radiation approach aims to tame pituitary tumors with fewer side effects
Disease control CompletedThis study tested a new way of delivering radiation for people with non-secreting pituitary adenomas that came back or remained after surgery. Instead of a single high dose, the radiation was given in five smaller daily doses. The goal was to see if this approach could control tu…
Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Immunotherapy combo shows promise for tough bile duct cancer
Disease control CompletedThis study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (gemcitabine/cisplatin) helps people with advanced bile duct or gallbladder cancer live longer. Over 1,000 participants received either the combination or chemo plus a placebo. The goal…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New combo therapy shows promise for hard-to-treat thyroid cancer
Disease control CompletedThis study tested whether combining targeted drugs (trametinib and dabrafenib) with radioactive iodine can help shrink or control advanced thyroid cancer that has stopped responding to standard radioactive iodine treatment. The trial enrolled 40 adults with specific gene mutation…
Phase 2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
High-dose radiation beams target liver tumors with precision
Disease control CompletedThis study tested a high-precision radiation treatment called stereotaxic radiotherapy (CyberKnife) in 44 adults with a single liver cancer tumor. The goal was to stop the tumor from growing for at least 18 months. Participants received three high-dose radiation sessions over 8-1…
Phase 2 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug cocktail shows promise for tough bile duct cancer
Disease control CompletedThis study tested a combination of the targeted drug regorafenib with chemotherapy (mGEMOX) in 66 people with advanced bile duct cancer that could not be removed by surgery. The main goal was to find the safest dose and check for side effects. This is not a cure, but aims to cont…
Phase 1/2 • Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for liver cancer: triple therapy shows promise
Disease control CompletedThis study tests whether adding a third drug, ipilimumab, to the standard two-drug combination (atezolizumab and bevacizumab) improves survival and tumor shrinkage in people with advanced liver cancer. About 229 patients will receive either the standard two drugs or all three. Th…
Phase 2/3 • Sponsor: Federation Francophone de Cancerologie Digestive • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Virus engineered to fight cancer shows promise in early trial
Disease control CompletedThis early-stage trial tested a modified virus called TILT-123 in 32 people with advanced solid tumors that had not responded to standard treatments. The virus is designed to infect and kill cancer cells while releasing immune-boosting proteins. The main goal was to check safety …
Phase 1 • Sponsor: TILT Biotherapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Epigenetic and immune drugs join forces against tough tumors
Disease control CompletedThis completed Phase 2 trial tested whether combining an immunotherapy drug (durvalumab) with an epigenetic drug (tazemetostat) can control advanced solid tumors like pancreatic, colorectal, and soft-tissue sarcoma. The study enrolled 164 adults and measured how well the combo sh…
Phase 2 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Real-World check: does zepzelca help advanced lung cancer patients?
Disease control CompletedThis study followed 272 adults with extensive-stage small cell lung cancer who were taking the drug Zepzelca. Researchers wanted to see how well the drug worked and how safe it was in real-world settings, not just in controlled trials. The goal was to measure tumor shrinkage, sur…
Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New combo shows promise for rare thymic cancer
Disease control CompletedThis study tested a combination of two drugs, pembrolizumab and lenvatinib, in 43 people with advanced thymic carcinoma or a related thymoma that had worsened after standard chemotherapy. The goal was to see if the combination could stop or slow cancer growth. Participants receiv…
Phase 2 • Sponsor: MedSIR • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New combo aims to stop liver cancer recurrence in High-Risk patients
Disease control CompletedThis early-stage trial tested whether combining donafinib (a targeted therapy) with an anti-PD-1 antibody (an immunotherapy) can safely prevent liver cancer from coming back after surgery. It involved 30 patients with high-risk features like microvascular invasion or multiple tum…
Phase 1 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New technique shields healthy liver during cancer radiation
Disease control CompletedThis study tested a method to protect healthy liver tissue during Yttrium-90 radioembolization, a radiation treatment for liver cancer. Doctors injected short-acting gelatin particles into arteries supplying non-cancerous liver areas to temporarily block blood flow. The goal was …
Sponsor: Next Biomedical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New injection attacks tumors from inside out
Disease control CompletedThis early-stage trial tested an experimental drug called CyPep-1, injected directly into tumors, either alone or with the immunotherapy pembrolizumab. The study involved 60 adults with advanced solid cancers that had stopped responding to standard treatments. The main goals were…
Phase 1/2 • Sponsor: Cytovation AS • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo shows promise in controlling Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental drug called VS-6766, given alone or with everolimus, in 104 adults with advanced solid tumors or multiple myeloma that had stopped responding to standard treatments. The goal was to find a safe, tolerable dosing schedule and measure h…
Phase 1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Drug combo shows promise for tough cancers
Disease control CompletedThis early-phase trial tested a combination of two drugs—pembrolizumab (an immunotherapy) and nintedanib (a drug that blocks blood vessel growth)—in 196 adults with advanced solid tumors that had worsened after standard treatment. The main goal was to find the safest dose of nint…
Phase 1 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Microwave ablation boosts immunotherapy in advanced liver cancer study
Disease control CompletedThis study looked at 52 adults with advanced liver cancer to see if adding microwave ablation (MWA) to immunotherapy works better than immunotherapy alone. MWA uses heat to destroy tumors and may help the immune system fight cancer more effectively. The researchers measured how l…
Sponsor: The First People's Hospital of Neijiang • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Chemo-Immuno cocktail shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested whether adding two chemotherapy drugs (6-mercaptopurine and 6-thioguanine) to an immunotherapy drug (Atezolizumab) could help treat advanced solid tumors that have stopped responding to standard treatments. The study enrolled 18 adults with metastati…
Phase 1/2 • Sponsor: Kristoffer Rohrberg • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Radiation beads aim to shrink liver tumors in neuroendocrine cancer trial
Disease control CompletedThis phase II trial tested a treatment called TheraSphere selective internal radiation therapy (SIRT) in 24 patients with neuroendocrine tumors that had spread to the liver and could not be surgically removed. The treatment involves injecting tiny radioactive beads into the liver…
Phase 2 • Sponsor: Imperial College London • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Liver cancer remission: is surgery still needed?
Disease control CompletedThis study looked at liver cancer patients whose tumors shrank completely after non-surgical treatments like chemoembolization and immunotherapy. Researchers compared those who then had surgery to remove any remaining tissue versus those who simply watched and waited. The goal wa…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Triple drug cocktail shows promise for untreated liver cancer
Disease control CompletedThis study tested whether adding a third drug (relatlimab) to a two-drug combination (nivolumab and bevacizumab) is safe and works better for people with advanced liver cancer who haven't had treatment before. The 83 participants received either the three-drug combo or the two-dr…
Phase 1/2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New cancer drug MRX-2843 enters first human trial
Disease control CompletedThis early-stage trial tested a new drug called MRX-2843 in 42 adults with advanced solid tumors that had spread or come back after other treatments. The main goal was to check safety and find the right dose. Researchers monitored side effects and how the drug moved through the b…
Phase 1 • Sponsor: Meryx, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New 'Smart' cut during ERCP aims to slash complication rates
Disease control CompletedThis study tested a new way to open the bile duct during an ERCP procedure. Instead of the standard pull-type cut, doctors used a special hooked knife (ASD) designed to cut only the circular muscle layer, potentially causing less damage. Over 1,500 patients were randomly assigned…
Sponsor: Military Medical Clinical Center of the Southern Region, Ukraine • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug ZGGS15 tested in patients with advanced cancers
Disease control CompletedThis early-stage trial tested a new biologic drug called ZGGS15 in 22 adults with advanced solid tumors who had no standard treatment options left. The main goals were to check safety, find the right dose, and look for early signs that the drug might control tumor growth. Partici…
Phase 1 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New pill shows promise in early trial for tough cancers
Disease control CompletedThis early-phase study tested an experimental oral drug called Q702 in 51 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects, while also looking at whether the drug could shrink …
Phase 1 • Sponsor: Qurient Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New combo treatment shows promise for inoperable liver cancer
Disease control CompletedThis study tested a new treatment for people with liver cancer that cannot be removed by surgery. The treatment combines chemotherapy delivered directly to the liver, a procedure to block the tumor's blood supply, and two drugs (lenvatinib and tislelizumab). The goal was to see i…
Phase 2 • Sponsor: Guangxi Medical University • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Immunotherapy combo shows promise in advanced liver cancer
Disease control CompletedThis study tested two immunotherapy drugs, nivolumab and ipilimumab, in people with advanced liver cancer that could not be treated with surgery. The goal was to see if these drugs could shrink tumors and control the disease. The trial included 657 adults and found that the treat…
Phase 1/2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Robot surgeons take on pancreatic cancer in major trial
Disease control CompletedThis study compared robotic-assisted pancreatic surgery to the standard open approach for people with pancreatic and related tumors. Researchers wanted to see if robotic surgery could help patients recover faster after the operation. A total of 268 patients took part across multi…
Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New immunotherapy cocktail shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-stage study tested a fixed-dose combination of two immunotherapy drugs (relatlimab and nivolumab) in 24 Chinese patients with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, how the drugs move through the b…
Phase 1/2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New hope for liver cancer patients: cabozantinib safety trial shows promise
Disease control CompletedThis study looked at how safe the drug cabozantinib is for people with advanced liver cancer (hepatocellular carcinoma) who have already tried another treatment called sorafenib. A total of 110 adults took part. The main goal was to see how long patients lived after starting cabo…
Phase 4 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New hope for liver cancer patients with damaged livers?
Disease control CompletedThis study tested a drug called tislelizumab in 50 people with advanced liver cancer who also have moderate liver damage (Child-Pugh B). The goal was to see if the drug could shrink tumors. Tislelizumab works by helping the immune system attack cancer cells. The study took place …
Phase 2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested a new immunotherapy drug called BDB001, alone or combined with atezolizumab (Tecentriq), in 40 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the best dose, and see if t…
Phase 1 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested a new immunotherapy drug called BDB001, both alone and combined with pembrolizumab, in 87 adults with advanced solid tumors that had progressed after standard treatments. The main goals were to check safety and find the best dose. The study is comple…
Phase 1 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Cancer drug tazemetostat gets Long-Term safety check in rollover trial
Disease control CompletedThis study offers continued access to tazemetostat for 58 people with various cancers who already benefited from the drug in earlier trials. The main goal is to monitor long-term safety and side effects. Participants must have shown clinical benefit from tazemetostat before joini…
Phase 1/2 • Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control CompletedThis study tested a new oral drug called RP-3500 (camonsertib), alone or combined with talazoparib or gemcitabine, in 276 adults with advanced solid tumors that have certain genetic mutations. The main goals were to find the safest dose and check for early signs of tumor shrinkag…
Phase 1/2 • Sponsor: Repare Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Could a smarter chemo schedule help kids beat cancer?
Disease control CompletedThis early-phase trial tested a chemotherapy regimen called DA-EPOCH-R in 4 children with certain B-cell cancers (DLBCL, PMBCL, or PTLD). The drugs are given as a continuous infusion over several days, and doses are adjusted based on how the child's body handles them. The goal wa…
Early phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug shows promise for cortisol disorder
Disease control CompletedThis study tested an experimental drug called SPI-62 in 26 adults with Cushing's syndrome caused by a non-adrenal tumor. The goal was to see if SPI-62 could lower cortisol levels safely. Participants received either SPI-62 or a placebo for 24 weeks, with an option to continue lon…
Phase 2 • Sponsor: Sparrow Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Old drug shows new promise against Post-Surgery fluid buildup
Disease control CompletedThis study tested whether a 6-day infusion of somatostatin, a drug that lowers pressure in the liver's blood vessels, could prevent ascites (fluid buildup) after liver cancer surgery. 179 patients with liver cancer and underlying liver disease took part. The goal was to see if so…
Phase 3 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New drug combo shows promise for Tough-to-Treat bile duct cancer
Disease control CompletedThis phase 2 trial tested a new chemotherapy combination (Nal-IRI with 5-FU and leucovorin) against a standard treatment (gemcitabine plus cisplatin) in 93 people with advanced biliary tract cancer that could not be removed by surgery. The study aimed to see which approach better…
Phase 2 • Sponsor: AIO-Studien-gGmbH • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Triple-Drug cocktail shows promise for tough bile duct cancer
Disease control CompletedThis study tested a combination of three drugs—chemotherapy (mFOLFOX6), an immunotherapy (atezolizumab), and a targeted therapy (bevacizumab)—in 20 people with advanced bile duct cancer who had already received one prior treatment. The goal was to see if the combination could shr…
Phase 1/2 • Sponsor: University Hospital, Essen • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Could a bone marrow shield make chemotherapy safer for lung cancer patients?
Disease control CompletedThis study tested a drug called trilaciclib in 123 people with advanced small cell lung cancer who were getting chemotherapy. The goal was to see if trilaciclib could protect the bone marrow and immune system from chemotherapy damage, reducing severe side effects like low white b…
Phase 1/2 • Sponsor: G1 Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New drug combo shows promise for untreated liver cancer
Disease control CompletedThis completed Phase 3 trial tested a combination of two drugs, atezolizumab and bevacizumab, in 152 people with advanced liver cancer that could not be surgically removed and had not been treated before. The goal was to check safety and how well the treatment works. The study wa…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New drug combo may reboot treatment for advanced liver cancer
Disease control CompletedThis study looked at 24 patients with advanced liver cancer whose disease got worse after standard treatment with lenvatinib and an immunotherapy drug. Researchers added a third drug, lenalidomide, to see if it could help control the cancer again. The goal was to measure how long…
Sponsor: Beijing Tsinghua Chang Gung Hospital • Aim: Disease control
Last updated Jun 26, 2026 19:15 UTC
-
New drug ZW25 shows promise for rare bile duct cancer
Disease control CompletedThis study tested a drug called ZW25 (zanidatamab) in 87 people with advanced or metastatic HER2-amplified biliary tract cancer that had worsened after standard chemotherapy. The goal was to see if the drug could shrink tumors and how long that effect lasted. The trial is now com…
Phase 2 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jun 26, 2026 17:24 UTC
-
New drug shows promise for Tough-to-Treat prostate cancer
Disease control CompletedThis early-stage trial tested a drug called Tarlatamab in 41 men with a rare and aggressive form of prostate cancer called neuroendocrine prostate cancer. The main goal was to check the drug's safety and find the best dose. The drug works by helping the body's immune cells recogn…
Phase 1 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 26, 2026 16:18 UTC
-
Hope for frail lung cancer patients: immunotherapy combo shows promise
Disease control CompletedThis study tested whether adding the immunotherapy drug atezolizumab to standard chemotherapy can help people with advanced small cell lung cancer who are in poor health. The trial included 70 patients with extensive-stage disease and a low performance status (ECOG 2). Researcher…
Phase 2 • Sponsor: AIO-Studien-gGmbH • Aim: Disease control
Last updated Jun 26, 2026 15:06 UTC
-
Wrist access may ease liver cancer treatment
Disease control CompletedThis study tested a new way to deliver chemo directly to liver tumors using a wrist artery instead of the groin. Thirty-eight patients with liver cancer took part. The goal was to see if the wrist approach is safe, feasible, and effective, with fewer complications and faster reco…
Sponsor: Asan Medical Center • Aim: Disease control
Last updated Jun 26, 2026 14:47 UTC
-
New drug aims to tame cortisol overload from adrenal tumors
Disease control CompletedThis Phase 3 trial tested a drug called relacorilant in 137 people with hypercortisolism caused by adrenal adenomas or hyperplasia. The goal was to see if it could improve blood sugar control and lower high blood pressure. Participants received either relacorilant or a placebo fo…
Phase 3 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Jun 26, 2026 14:09 UTC
-
Experimental Vaccine-Like therapy targets Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental immunotherapy called ELI-002 in 25 people with KRAS-mutated pancreatic, colorectal, lung, ovarian, or bile duct cancers who had signs of remaining disease after standard treatment. The therapy aims to train the immune system to attack…
Phase 1 • Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated Jun 26, 2026 13:30 UTC
-
New hope for rare, aggressive cancer: drug cocktail shows promise in trial
Disease control CompletedThis study tested whether adding the drug bevacizumab (Avastin) to standard chemotherapy (Folfiri) helps people with advanced, aggressive neuroendocrine carcinoma live longer after their first treatment stops working. The trial included 153 adults with inoperable cancer that star…
Phase 2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 26, 2026 13:11 UTC
-
Diabetes drug januvia tested to boost immune attack on liver cancer
Disease control CompletedThis pilot study tested the safety of giving sitagliptin (Januvia) for three weeks to 14 liver cancer patients before they had surgery to remove their tumors. The idea is that sitagliptin might help immune cells get into the tumor and fight it better. The main goal was to check f…
Phase 1 • Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Disease control
Last updated Jun 26, 2026 12:57 UTC
-
Two blood markers put to the test for early liver cancer detection
Diagnosis CompletedResearchers at Hanoi Medical University are studying whether two blood markers, AFP-L3 and PIVKA-II, can accurately detect hepatocellular carcinoma, the most common form of liver cancer. The trial enrolls 200 adults, including people with liver cancer and people with benign liver…
Sponsor: Hanoi Medical University • Aim: Diagnosis
Last updated Sep 18, 2026 00:00 UTC
-
A single blood draw to detect five cancers before symptoms appear?
Diagnosis CompletedThis trial tests a blood-based test designed to detect multiple cancers early in people aged 40 to 74 who have no cancer symptoms. The study will enroll about 2,500 participants and will check how well the test identifies lung, colorectal, liver, gastric, and esophageal cancers. …
Sponsor: Shanghai Weihe Medical Laboratory Co., Ltd. • Aim: Diagnosis
Last updated Sep 06, 2026 00:00 UTC
-
A simple blood draw could spot tumor relapse before scans do
Diagnosis CompletedThis study tests whether measuring gene transcripts in the blood can help diagnose neuroendocrine tumors and assess how completely surgery removed them. Researchers will track blood levels after surgery and compare them with imaging to see if a rise in these markers signals tumor…
Sponsor: Wren Laboratories LLC • Aim: Diagnosis
Last updated Aug 23, 2026 00:00 UTC
-
Can a prostate cancer scan also spot liver tumors?
Diagnosis CompletedThis trial is testing whether a special PET/CT scan, typically used for prostate cancer, can better detect hepatocellular carcinoma (the most common type of liver cancer) compared to standard CT or MRI scans. The study will enroll about 30 adults with liver lesions suspicious for…
Phase 2 • Sponsor: Peter MacCallum Cancer Centre, Australia • Aim: Diagnosis
Last updated Aug 20, 2026 00:00 UTC
-
Can a new PET scan light up hidden adrenal tumors causing high blood pressure?
Diagnosis CompletedThis trial is testing whether a new radioactive tracer, [18F]AlF-NOTA-pentixather, can accurately identify aldosterone-producing adenomas (benign adrenal tumors) in people with primary aldosteronism—a condition where the adrenal glands make too much aldosterone, leading to high b…
Sponsor: Sichuan Provincial People's Hospital • Aim: Diagnosis
Last updated Aug 20, 2026 00:00 UTC
-
Genetic test may spare patients from unnecessary thyroid surgery
Diagnosis CompletedThis study evaluates Thyroscan, a genomic test that analyzes genetic material from thyroid nodule samples, to see if it can accurately distinguish benign from malignant nodules. The trial involves 250 adults with suspicious thyroid nodules who are scheduled for surgery or have st…
Sponsor: Rigen Biotech • Aim: Diagnosis
Last updated Aug 16, 2026 00:00 UTC
-
Can AI help surgeons see thyroid cancer more clearly?
Diagnosis CompletedThis trial is testing whether an AI-assisted ultrasound system can help surgeons plan thyroid cancer surgery. People scheduled for thyroid surgery will receive a standard ultrasound followed by an AI-assisted repeat exam. The AI identifies and scores thyroid nodules, and the stud…
Sponsor: Fujian Medical University • Aim: Diagnosis
Last updated Aug 09, 2026 00:00 UTC
-
Can AI read tumor slides to outsmart childhood cancer?
Diagnosis CompletedThis trial is testing whether an artificial intelligence (AI) model can accurately diagnose and grade several types of solid tumors that affect children, including neuroblastoma, medulloblastoma, Wilms tumor, hepatoblastoma, and rhabdomyosarcoma. The AI is trained on thousands of…
Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Diagnosis
Last updated Aug 06, 2026 00:00 UTC
-
New screening strategy could speed diagnosis of inherited aldosteronism
Diagnosis CompletedThis study tests a new screening method to tell apart two causes of high blood pressure: a rare genetic condition called Glucocorticoid-Remediable Aldosteronism (GRA) and a more common adrenal tumor. The approach combines an overnight dexamethasone suppression test with detailed …
Sponsor: Peking Union Medical College Hospital • Aim: Diagnosis
Last updated Jul 16, 2026 00:00 UTC
-
New PET tracer could spot hidden thyroid cancer
Diagnosis CompletedThis study tested whether a special PET scan tracer called 18F-DOPA can better detect leftover medullary thyroid cancer in lymph nodes after surgery, compared to standard imaging. Twenty-four adults with elevated thyrocalcitonin levels (a sign of residual disease) received the tr…
Sponsor: Institut Claudius Regaud • Aim: Diagnosis
Last updated Jun 28, 2026 00:00 UTC
-
New scan could reveal hidden cancer cells
Diagnosis CompletedThis early study tested a radioactive imaging agent called [99mTc]Tc(CO)3-(HE)3-Ec1 in 10 adults with solid tumors. The agent is designed to attach to EpCAM receptors on cancer cells, making them visible on SPECT scans. Researchers aimed to see where the agent goes in the body, m…
Phase 1 • Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences • Aim: Diagnosis
Last updated Jun 27, 2026 14:03 UTC
-
New blood test may spot liver cancer sooner in High-Risk patients
Diagnosis CompletedThis study looked at 639 adults with cirrhosis to see if a blood test called mSEPT9 can detect liver cancer (hepatocellular carcinoma) better than the current standard test (AFP). Participants gave an extra blood sample during routine care, and researchers compared how well each …
Sponsor: Central Hospital, Nancy, France • Aim: Diagnosis
Last updated Jun 27, 2026 13:07 UTC
-
New scan lights up hidden gut tumors
Diagnosis CompletedThis completed Phase 3 trial tested a special PET-CT scan using a radioactive tracer called gallium-68 DOTATOC to find neuroendocrine tumors in the stomach, intestines, and pancreas. 69 adults with confirmed or suspected tumors received the scan. The goal was to see how accuratel…
Phase 3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Diagnosis
Last updated Jun 27, 2026 13:07 UTC
-
New imaging agent could sharpen detection of rare tumors
Diagnosis CompletedThis early-phase study tested a new way to make a radioactive tracer called 68Ga-DOTATOC for PET-CT scans in 20 adults with suspected or known neuroendocrine tumors. The goal was to see if this new method could find tumors more accurately than the current standard scan (OctreoSca…
Phase 1 • Sponsor: University Hospital, Bordeaux • Aim: Diagnosis
Last updated Jun 27, 2026 13:05 UTC
-
New scan could spot hidden tumors
Diagnosis CompletedThis early study tested a new radioactive tracer called [18F]3F-PHPG to see if it can help locate neuroendocrine tumors during PET scans. 32 adults with these tumors received the tracer and had two scans. The goal was to check image quality and how the tracer spreads in the body,…
Early phase 1 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 13:04 UTC
-
New biopsy technique may spot hidden abdominal cancers without major surgery
Diagnosis CompletedThis study looked at how well a special biopsy method called EUS-FNB can diagnose hard-to-reach tumors in the abdomen, such as those near the bile duct or small intestine. Researchers reviewed data from 131 patients who had this procedure over 10 years. The goal was to see if thi…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Diagnosis
Last updated Jun 27, 2026 13:01 UTC
-
Which biopsy method best spots bile duct cancer?
Diagnosis CompletedThis study looked at different ways to take tissue samples from the bile duct during a procedure called ERCP. The goal was to see which method is most accurate for finding cancer. 327 adults with unclear bile duct narrowing took part. Researchers compared several biopsy technique…
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 12:36 UTC
-
New ultrasound trick spots liver cancer treatment success days earlier
Diagnosis CompletedThis study tested a new ultrasound technique (Side-by-Side Contrast-Enhanced Ultrasound) to see if it could accurately check whether microwave ablation fully destroyed liver tumors just 1-3 days after treatment. Researchers compared it to standard contrast-enhanced ultrasound in …
Sponsor: The First Hospital of Jilin University • Aim: Diagnosis
Last updated Jun 27, 2026 12:35 UTC
-
AI takes on radiologists: can a computer beat the standard for liver cancer diagnosis?
Diagnosis CompletedThis study tested a new artificial intelligence (AI) algorithm against the standard LI-RADS criteria for diagnosing liver cancer (hepatocellular carcinoma) on CT scans. Researchers enrolled 300 people at risk for liver cancer who had a new liver nodule found on ultrasound. The go…
Sponsor: The University of Hong Kong • Aim: Diagnosis
Last updated Jun 27, 2026 12:33 UTC
-
Minutes, not days: new rapid test could speed up thyroid cancer detection
Diagnosis CompletedThis study tested a new rapid test that checks for thyroid cancer spread to neck lymph nodes in just minutes, instead of the usual days-long wait. Researchers studied 250 adults with suspected or known thyroid cancer, comparing the quick test to standard lab methods. The goal was…
Sponsor: Soroka University Medical Center • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
Blow into this tube: a simple breath test might spot liver disease early
Diagnosis CompletedThis study looked at whether a breath test could help detect liver fibrosis, cirrhosis, or liver cancer. Researchers collected breath samples from 56 patients with known or suspected liver disease and analyzed them for specific chemical markers. The goal was to see if the test co…
Sponsor: Imperial College London • Aim: Diagnosis
Last updated Jun 27, 2026 12:02 UTC
-
New blood test could spot hidden liver cancer early
Diagnosis CompletedThis completed study tested a new blood test that looks for tiny particles called exosomal microRNAs to detect intrahepatic cholangiocarcinoma, a rare and aggressive liver cancer. Researchers analyzed blood samples from 535 adults to see how accurately the test could identify can…
Sponsor: City of Hope Medical Center • Aim: Diagnosis
Last updated Jun 27, 2026 11:01 UTC
-
New blood test could spare bile duct cancer patients unnecessary surgery
Diagnosis CompletedThis study tested a new blood test called LyMIC that looks for tiny particles (exosomes) released by cancer cells. The goal was to see if it could accurately tell whether bile duct cancer has spread to nearby lymph nodes before surgery. Researchers analyzed blood samples from 230…
Sponsor: City of Hope Medical Center • Aim: Diagnosis
Last updated Jun 27, 2026 11:00 UTC
-
New blood test could spot hidden tumors causing high blood pressure
Diagnosis CompletedThis study looked at whether a new blood marker called EM66 can help doctors tell the difference between high blood pressure caused by rare adrenal tumors (pheochromocytoma or paraganglioma) and regular high blood pressure. Researchers measured EM66 levels in 60 adults with eithe…
Sponsor: University Hospital, Rouen • Aim: Diagnosis
Last updated Jun 27, 2026 09:02 UTC
-
New PET tracer could sharpen cancer detection
Diagnosis CompletedThis study tested a new radioactive tracer called [18F]FAPI-74 for PET scans in people with gastrointestinal cancers, including liver, bile duct, stomach, pancreatic, and colorectal cancers. The goal was to see if the tracer can accurately detect cancer cells by comparing scan re…
Phase 2 • Sponsor: SOFIE • Aim: Diagnosis
Last updated Jun 27, 2026 08:13 UTC
-
Could a simple saliva test replace blood draws for cortisol screening?
Diagnosis CompletedThis study looked at whether a saliva test can accurately measure cortisol levels after a dexamethasone suppression test, compared to the standard blood test. Researchers studied about 100 patients with adrenal incidentalomas (non-cancerous growths on the adrenal gland) and 100 h…
Sponsor: Rigshospitalet, Denmark • Aim: Diagnosis
Last updated Jun 27, 2026 08:12 UTC
-
New PET/MRI scan could spot elusive brain tumors in Cushing's patients
Diagnosis CompletedThis study tested whether a special scan called [11C]-Methionine PET/MRI can better locate tiny pituitary tumors that cause Cushing's disease. Standard MRI often misses these tumors, leading to risky exploratory surgery. The study involved 33 adults with confirmed Cushing's disea…
Sponsor: Hospices Civils de Lyon • Aim: Diagnosis
Last updated Jun 27, 2026 07:51 UTC
-
Can everyday drugs shield the liver from Cirrhosis's worst threats?
Prevention CompletedThis clinical trial investigates whether two existing medications, allopurinol and atorvastatin, can help prevent serious complications in people with stable liver cirrhosis. The study will compare these drugs against a placebo to see if they reduce the number of acute decompensa…
Phase 2/3 • Sponsor: Tanta University • Aim: Prevention
Last updated Aug 13, 2026 00:00 UTC
-
Can a pill shield ears from chemo damage?
Prevention CompletedThis study tests whether the drug SENS-401 can prevent hearing loss caused by cisplatin, a common chemotherapy. Adults with cancer who are scheduled to receive cisplatin take SENS-401 before, during, and after treatment. Hearing is measured with a standard test to see if the drug…
Phase 2 • Sponsor: Sensorion • Aim: Prevention
Last updated Jul 04, 2026 00:00 UTC
-
New catheter lock could slash infection risk for cancer patients
Prevention CompletedThis study tested whether a taurolidine-citrate solution (TauroLock) placed in the catheter between treatments can prevent bloodstream infections in adults with solid tumors receiving IV anti-cancer therapy. 162 patients were randomly assigned to get either the TauroLock solution…
Sponsor: Centre Hospitalier Régional Metz-Thionville • Aim: Prevention
Last updated Jun 27, 2026 14:02 UTC
-
Virtual fitness and nutrition program aims to keep older men on their feet
Prevention CompletedThis pilot study tested a virtual program designed to help older men at high risk for fractures reduce their risk of falls and broken bones. The program included personalized exercise plans delivered through a smartphone app and virtual nutrition counseling. Researchers enrolled …
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Prevention
Last updated Jun 27, 2026 12:10 UTC
-
Probiotics show promise in stopping autoimmune diseases before they start
Prevention CompletedThis study tested whether giving a daily mix of two types of friendly bacteria (Lactobacilli) to children at genetic risk could prevent or slow down autoimmune diseases like celiac disease, type 1 diabetes, and thyroid problems. The researchers enrolled 202 children who already h…
Sponsor: Lund University • Aim: Prevention
Last updated Jun 27, 2026 12:06 UTC
-
Can a pre-surgery spray fix post-op sleep? new trial investigates
Symptom relief CompletedThis study tests whether giving dexmedetomidine—either as a nasal spray or through an IV—before thyroid surgery can improve sleep quality afterward. 120 adults undergoing thyroid removal will be randomly assigned to one of two drug groups or a placebo. The goal is to see if this …
Phase 1/2 • Sponsor: The Second People's Hospital of Huai'an • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Lower dose of olanzapine may ease chemo nausea with less drowsiness
Symptom relief CompletedThis study looked at 2,000 adults with solid tumors to find the best dose of olanzapine for preventing nausea and vomiting caused by strong chemotherapy. Researchers compared 2.5 mg, 5 mg, and 10 mg doses to see which works best with the fewest side effects like daytime sleepines…
Sponsor: Shandong Cancer Hospital and Institute • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Ear zaps may Kick-Start stomach after pancreatic surgery
Symptom relief CompletedThis study tested whether a device that gently stimulates the vagus nerve through the ear could reduce delayed stomach emptying after a major pancreatic surgery (pancreaticoduodenectomy). 84 patients were randomly assigned to receive the stimulation during surgery or not. The goa…
Sponsor: Affiliated Hospital of Nantong University • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
Mushroom powder may lift mood in thyroid cancer survivors
Symptom relief CompletedThis study tests whether a mushroom supplement called Ganoderma lucidum spore powder can reduce depression in women who have had thyroid cancer surgery. Three hundred participants will take either the supplement or a placebo daily for three months. Researchers will measure change…
Sponsor: Ling Zhiqiang • Aim: Symptom relief
Last updated Aug 30, 2026 00:00 UTC
-
Can an AI chatbot lift the spirits of advanced cancer patients?
Symptom relief CompletedThis trial tests whether an AI emotional companion app can improve depression, anxiety, and demoralization in adults with advanced cancer. Participants use a mobile app where a virtual character holds conversations, reads emotional cues, and offers a link to a human hotline if di…
Sponsor: National Yang Ming Chiao Tung University • Aim: Symptom relief
Last updated Aug 30, 2026 00:00 UTC
-
A card game could open the door to better End-of-Life conversations
Symptom relief CompletedThis study tests whether a conversation game called 'Hello' can help people with cancer and their loved ones discuss advance care planning—decisions about future medical care. Participants will play either the Hello game or a similar conversation game, complete questionnaires, an…
Sponsor: Milton S. Hershey Medical Center • Aim: Symptom relief
Last updated Aug 23, 2026 00:00 UTC
-
Can light therapy unblock a common cancer side effect?
Symptom relief CompletedThis trial tests whether laser acupuncture, a non-invasive therapy using low-intensity light on traditional acupoints, can relieve constipation in people with advanced cancer. Participants are adults with advanced cancer who have constipation despite using laxatives. The study me…
Sponsor: Chang Gung Memorial Hospital • Aim: Symptom relief
Last updated Aug 22, 2026 00:00 UTC
-
Safer pain relief after liver surgery? new block tested against epidural
Symptom relief CompletedThis study compares two ways to manage pain after open liver surgery: a newer erector spinae plane block (ESPB) and the standard thoracic epidural. Sixty adults having elective open liver resection will be randomly assigned to one method. The goal is to see if ESPB provides simil…
Sponsor: Nguyen Toan Thang • Aim: Symptom relief
Last updated Aug 21, 2026 00:00 UTC
-
Peppermint and lemon scents put to the test against chemo nausea
Symptom relief CompletedThis phase 2 trial tests whether inhaling a blend of peppermint and lemon essential oils can reduce nausea and vomiting in people receiving their first chemotherapy for a solid tumor. Participants will inhale the oils four times daily and whenever nausea strikes, with symptoms tr…
Phase 2 • Sponsor: Centre Francois Baclesse • Aim: Symptom relief
Last updated Aug 19, 2026 00:00 UTC
-
A digital lifeline: could Real-Time symptom tracking transform care for kids with advanced cancer?
Symptom relief CompletedThis trial tests whether a new care approach, called PediQUEST Response, can improve quality of life for children, adolescents, and young adults with advanced cancer. Participants use an app to regularly report symptoms and quality of life, and a palliative care team receives the…
Sponsor: Joanne Wolfe, MD, MPH • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
Virtual reality goggles could ease cancer Patients' procedure fears
Symptom relief CompletedThis study tests whether using a virtual reality headset during PICC line placement can reduce anxiety and pain in cancer patients. About 120 adults will be randomly assigned to either receive VR plus standard care or standard care alone. The goal is to see if this non-drug appro…
Sponsor: Istituto Oncologico Veneto IRCCS • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
Which palliative care approach boosts quality of life in advanced lung cancer?
Symptom relief CompletedThis study looks at two ways of delivering palliative care—specialized support to ease symptoms and stress—for people recently diagnosed with advanced lung cancer. One approach starts with basic palliative care and adds more if needed, while the other provides full palliative car…
Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
Can talking it out ease PTSD in cancer patients during a pandemic?
Symptom relief CompletedThis study tested whether monthly 45-minute psychological interviews over 6 months could reduce post-traumatic stress symptoms in cancer patients affected by the COVID-19 pandemic. It included 29 adults with solid tumors who had moderate to high PTSD symptoms. The goal was to see…
Sponsor: Centre Francois Baclesse • Aim: Symptom relief
Last updated Aug 02, 2026 00:00 UTC
-
Can removing the catheter early speed up liver surgery recovery?
Symptom relief CompletedThis trial investigates whether removing a urinary catheter within 6 hours after laparoscopic liver surgery, as part of an enhanced recovery program, improves urinary function and reduces complications. About 212 adults aged 18 to 75 with benign or malignant liver tumors schedule…
Sponsor: Yu Zhang • Aim: Symptom relief
Last updated Jul 31, 2026 00:00 UTC
-
Sweet relief? candy and honey may shield salivary glands from radiation damage
Symptom relief CompletedThis trial tests whether sucking lemon candy and using honey mouthwash can reduce salivary gland damage caused by radioiodine therapy for thyroid cancer. About 120 adults who have had their thyroid removed and are about to receive radioiodine will be randomly assigned to the cand…
Sponsor: Cyprus University of Technology • Aim: Symptom relief
Last updated Jul 30, 2026 00:00 UTC
-
Can a sedative calm the Body's stress response during brain tumor surgery?
Symptom relief CompletedThis phase 2 trial tests whether giving the sedative dexmedetomidine during pituitary tumor surgery can dampen the body's stress response and improve early recovery. About 64 adults with non-functioning pituitary adenomas undergoing endoscopic transsphenoidal surgery will be rand…
Phase 2 • Sponsor: Seoul National University Hospital • Aim: Symptom relief
Last updated Jul 25, 2026 00:00 UTC
-
Could a smartphone app speed up recovery after thyroid surgery?
Symptom relief CompletedThis study tests whether a mobile app that provides education and support before and after thyroid surgery can improve recovery and quality of life. Participants are adults having their first thyroidectomy who own a smartphone. One group gets standard care, while the other also u…
Sponsor: Ataturk University • Aim: Symptom relief
Last updated Jul 19, 2026 00:00 UTC
-
Could tiny needles tame Chemo's Gut-Wrenching side effect in kids?
Symptom relief CompletedThis study tests whether acupuncture using tiny, semi-permanent needles can prevent diarrhea caused by the chemotherapy drug irinotecan in children with solid tumors. About 22 children will receive the acupuncture during their second round of chemo, and researchers will measure p…
Sponsor: Fundació Sant Joan de Déu • Aim: Symptom relief
Last updated Jul 11, 2026 00:00 UTC
-
Ancient Mind-Body practice tested as fatigue fighter for men after cancer
Symptom relief CompletedThis study investigates whether a 12-week program of tai chi and qigong (called Body Mind Training) can reduce fatigue in male cancer survivors aged 55 and older. Participants are randomly assigned to the mind-body training, a light exercise-only group, or a usual-care group. Res…
Sponsor: Rutgers, The State University of New Jersey • Aim: Symptom relief
Last updated Jul 09, 2026 00:00 UTC
-
Talking therapy shows promise for MG patients with depression in tiny pilot study
Symptom relief CompletedThis study looked at whether having a tendency toward depression affects how well people with thymoma-associated myasthenia gravis (MG) respond to psychological counseling. Nineteen adults who had surgery for thymoma and MG received eight sessions of counseling based on Gestalt t…
Sponsor: Ming-Hsing Chang • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
No-Drain thyroid surgery shows promise for benign nodules
Symptom relief CompletedThis study looked at whether removing benign thyroid nodules without placing a surgical drain is safe and effective. Eighty adults having thyroid surgery were randomly assigned to either the standard drain or a no-drain, sutureless technique. The goal was to see if the no-drain a…
Sponsor: Minia University • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
Simple muscle relaxation technique shows promise for thyroid cancer pain
Symptom relief CompletedThis study tested whether a simple relaxation exercise, called progressive muscle relaxation (PMR), could help reduce pain and improve quality of life in people with thyroid cancer. Thirty-two patients undergoing chemotherapy were randomly assigned to do either PMR plus gentle st…
Sponsor: University of Faisalabad • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
String-Attached stent may ease bile duct cancer surgery prep
Symptom relief CompletedThis pilot study tested a plastic stent with a retrieval string to drain bile in 40 people with resectable bile duct cancer. The goal was to see if the stent could safely reduce bile buildup before surgery. Researchers measured serious complications and how well the stent worked.
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
Laser and Light-Sensitive drug shrink lung tumors in early trial
Symptom relief CompletedThis early-phase trial tested a treatment called photodynamic therapy for people with advanced lung cancer that blocks airways. Patients received a light-sensitive drug followed by a laser to activate it inside the tumor. The goal was to see if the treatment is safe and can shrin…
Phase 1/2 • Sponsor: Roswell Park Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC
-
New recovery plan cuts hospital time and pain after thyroid surgery
Symptom relief CompletedThis study tested a special recovery program (ERAS) for people having thyroid surgery. The goal was to see if it could reduce pain, nausea, and time spent in the hospital compared to usual care. 143 adults took part, and the program focused on improving comfort and speeding up re…
Sponsor: Assiut University • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
New pain coping program helps advanced cancer patients regain daily life
Symptom relief CompletedThis study tested a special pain coping skills program for people with advanced solid tumor cancer who have pain that interferes with daily activities. 211 patients were randomly assigned to either the program or standard care. The program taught ways to manage pain and find mean…
Sponsor: Duke University • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Lung cancer patients breathe easier with simple rehab program
Symptom relief CompletedThis study tested an 8-week supervised program of breathing exercises and light strength training for 30 people with advanced lung cancer (stage IIIB/IV) who were also getting chemotherapy. Those in the rehab group could walk farther, breathe better, and reported less coughing an…
Sponsor: Istanbul Medipol University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
Team nursing approach shows promise for lung cancer patients on immunotherapy
Symptom relief CompletedThis study tested a team-based nursing program for 200 people with advanced small cell lung cancer receiving chemotherapy plus immunotherapy. The program included close monitoring for side effects, help with medication adherence, nutrition and exercise support, and psychological …
Sponsor: Shanxi Province Cancer Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:02 UTC
-
Can a single pill ease pain after liver cancer procedure?
Symptom relief CompletedThis study tested whether giving a single dose of pregabalin before a liver cancer ablation procedure can reduce pain afterward. 70 adults with liver cancer were randomly assigned to receive either pregabalin or a placebo before their procedure. The main goal was to measure pain …
Phase 4 • Sponsor: Sherief Abd-Elsalam • Aim: Symptom relief
Last updated Jun 27, 2026 11:01 UTC
-
Talking through cancer: can couples therapy ease the emotional toll?
Symptom relief CompletedThis study tested a program that teaches couples communication skills when one partner has advanced cancer. About 440 patients and their partners took part, with half receiving the training and half getting general healthy living information. The goal was to see if the training c…
Sponsor: Duke University • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
Can a palliative care team boost quality of life for cancer surgery patients?
Symptom relief CompletedThis study looked at whether having a palliative care team work alongside surgeons improves quality of life for patients with gastrointestinal cancers like pancreatic or liver cancer. About 379 patients and their family members took part. The main goal was to see if this team app…
Sponsor: Stanford University • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
New nerve block combo could cut opioid use after thyroid surgery
Symptom relief CompletedThis study tested whether adding dexmedetomidine to a standard nerve block (superficial cervical plexus block) improves pain control after thyroid surgery. Fifty-eight adults undergoing thyroid surgery were randomly assigned to receive the nerve block with or without dexmedetomid…
Sponsor: Udayana University • Aim: Symptom relief
Last updated Jun 27, 2026 08:03 UTC
-
New study tests better comfort care for liver patients
Symptom relief CompletedThis study tested two approaches to bring palliative care (comfort-focused care) to people with end-stage liver disease. About 1,500 adults from 19 U.S. centers took part. One group had direct access to a palliative care specialist; the other group saw a liver doctor specially tr…
Sponsor: Albert Einstein Healthcare Network • Aim: Symptom relief
Last updated Jun 27, 2026 08:01 UTC
-
New online program eases Kids' cancer return to school
Symptom relief CompletedThis study tested a web-based program to help children aged 8-17 with cancer adjust to returning to school. The program included modules for children, parents, teachers, and peers, focusing on communication, coping, and social skills. Twenty children participated, and researchers…
Sponsor: Gazi University • Aim: Symptom relief
Last updated Jun 27, 2026 07:52 UTC
-
Virtual reality goggles calm nerves before thyroid surgery
Symptom relief CompletedThis study tested whether using a virtual reality headset with relaxing hypnosis techniques could lower stress in people about to have their thyroid removed. Eighty-two adults used the headset for 30 minutes before and after surgery. Researchers measured anxiety levels to see if …
Sponsor: Centre Francois Baclesse • Aim: Symptom relief
Last updated Jun 26, 2026 17:28 UTC
-
Zinc and cream combo may stop painful side effect of cancer treatment
Symptom relief CompletedThis study tested whether taking zinc supplements and applying a strong steroid cream (clobetasol) can prevent or reduce hand-foot skin reaction, a common and painful side effect of the cancer drug regorafenib. About 150 patients starting regorafenib were split into three groups:…
Sponsor: Gazi University • Aim: Symptom relief
Last updated Jun 26, 2026 17:04 UTC
-
Immunotherapy side effects under the microscope: MOTIVATE study tracks 150 patients
Knowledge-focused CompletedThis study followed 150 people with solid tumors who were starting immunotherapy (immune checkpoint inhibitors) as part of their regular care. Researchers collected data on side effects and asked patients to fill out questionnaires before each treatment. The goal was to better un…
Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Study maps out tumor detection in rare stomach condition
Knowledge-focused CompletedThis completed study looked at how to best find and manage tumors in people with Zollinger-Ellison syndrome, a rare condition that causes too much stomach acid. Researchers used imaging tests and tissue samples to locate tumors and check for a related genetic condition called MEN…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Should all young cancer patients get genetic testing? study investigates
Knowledge-focused CompletedThis study looked at whether offering genetic testing to all young adults with cancer (ages 18-39) is better than only testing those who meet certain guidelines. About 749 participants were randomly assigned to either universal testing with a broad gene panel or standard testing …
Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Mining Responders' tumors for clues to a universal cancer therapy
Knowledge-focused CompletedResearchers want to learn which molecules on cancer cells the immune system attacks when checkpoint inhibitor drugs work well. They collect tumor and blood samples from adults with solid tumors who respond to these drugs, either during treatment or after surgery. The team then se…
Sponsor: TScan Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Glow-in-the-dark dye may help surgeons spot hidden cancer in kids
Knowledge-focused CompletedThis study is testing whether a green dye called ICG can help surgeons see tumors more clearly during surgery in children and teens with solid tumors. The dye is injected before surgery and makes tumor tissue glow under a special camera. The goal is to see if this technique helps…
Phase 1 • Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Can a single dose of an antipsychotic disrupt blood sugar control?
Knowledge-focused CompletedThis trial tests whether a single dose of the antipsychotic drugs olanzapine or ziprasidone changes how the body responds to insulin, compared with a placebo. The study enrolls healthy young men who are overweight or have early signs of insulin resistance, but who have never take…
Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
Can a nationwide review unlock the secrets of a rare adrenal cancer?
Knowledge-focused CompletedThis study looks back at the medical records of 150 adults in Brazil diagnosed with adrenocortical carcinoma, a rare cancer of the adrenal glands. Researchers will collect details on age, gender, location, tumor stage, hormone activity, and treatments received since the year 2000…
Sponsor: Latin American Cooperative Oncology Group • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Scientists investigate why adrenal tumors produce hormones
Knowledge-focused CompletedThis study looked at adrenal gland tumors to understand why they form, why some release extra hormones, and why some are cancerous. Researchers studied 690 people with known or suspected adrenal tumors. Participants underwent tests like blood draws, imaging scans, and urine colle…
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Can patient records reveal who will respond to neuroendocrine tumor treatments?
Knowledge-focused CompletedThis study looks back at the medical records of 88 adults with neuroendocrine tumors that have spread or cannot be removed. Researchers will examine how different patient characteristics and treatments relate to overall survival and other outcomes. The goal is to identify factors…
Sponsor: Latin American Cooperative Oncology Group • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
Can the mediterranean diet survive chemo? new study investigates
Knowledge-focused CompletedThis study looked at how cancer treatment changes patients' ability to stick with a Mediterranean diet. Researchers followed 116 patients starting chemotherapy or immunotherapy, checking their diet adherence and sensory changes (taste and smell) at the start and after 9 weeks. Th…
Sponsor: Centre Antoine Lacassagne • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC
-
Liver cancer research aims to unlock secrets of immunotherapy response
Knowledge-focused CompletedThis study gathers blood, urine, stool, and tissue samples from 132 adults with primary liver cancer who are receiving or have received immunotherapy. Researchers will analyze these samples along with medical records to learn more about how liver cancer develops and responds to t…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC
-
Sharper scans may make cancer radiation more precise
Knowledge-focused CompletedThis study tested a new cone-beam CT scanner that takes clearer pictures during radiation therapy for lung, liver, and breast cancers. 31 people participated to see if the new scanner reduces image blurring and improves accuracy. The goal is to help doctors target tumors more pre…
Sponsor: Varian, a Siemens Healthineers Company • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC
-
Could being male or female change how a thyroid cancer drug works?
Knowledge-focused CompletedThis study looks at whether men and women with a certain type of advanced thyroid cancer (radioiodine-refractory differentiated thyroid cancer) experience different side effects and outcomes when treated with the drug lenvatinib. Researchers will compare dose reductions, side eff…
Sponsor: Regina Elena Cancer Institute • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC
-
A new tool aims to demystify immunotherapy for advanced cancer patients
Knowledge-focused CompletedThis trial tests whether a 15-minute educational video and a list of suggested questions can improve understanding of immunotherapy among patients with advanced cancer and their caregivers. Participants are randomly assigned to receive the educational materials or usual care, and…
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Aug 27, 2026 00:00 UTC
-
New study aims to decode cancer risk in treated thyroid nodules
Knowledge-focused CompletedThis study follows 180 people who had a benign thyroid nodule treated with radiofrequency heat ablation three years ago. Researchers will use ultrasound and a fine-needle biopsy to see how the nodule looks and whether any cells have changed. The goal is to create a better way to …
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Aug 21, 2026 00:00 UTC
-
New ultrasound test may predict dangerous pancreatic leaks after surgery
Knowledge-focused CompletedThis study is testing whether a special type of ultrasound, called endoscopic ultrasound elastography, can predict the texture of the pancreas and the risk of a pancreatic fistula after a major surgery called pancreaticoduodenectomy. The study will enroll 100 adults scheduled for…
Sponsor: Minia University • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC
-
A 5-minute quiz might predict who gets severe chemo side effects
Knowledge-focused CompletedThis study looks at whether a short risk-assessment tool, called the CARG score, can predict severe side effects from chemotherapy in cancer patients aged 70 and older. Participants will answer questions about their health and daily function before starting a new chemotherapy reg…
Sponsor: RenJi Hospital • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC
-
Michigan study tests ways to boost genetic testing in cancer patients
Knowledge-focused CompletedThis study looked at whether a special website or coaching phone calls could help more people with a personal or family history of certain cancers get genetic testing. Over 800 participants were randomly assigned to one of these two methods or to standard care. The goal was to se…
Sponsor: University of Michigan Rogel Cancer Center • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC
-
Blood test may spare cancer patients unneeded iron infusions
Knowledge-focused CompletedThis trial explores whether a blood test measuring reticulocyte hemoglobin content (RET-He) can predict how well cancer patients with anemia will respond to intravenous iron treatment. The study involves adults with solid tumors who have functional iron deficiency. By checking RE…
Sponsor: Institut Cancerologie de l'Ouest • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Massive Real-World study tracks Atezolizumab's performance in routine cancer care
Knowledge-focused CompletedThis study follows over 2,700 people with bladder, lung, or liver cancer who are receiving the drug atezolizumab as part of their normal treatment. Researchers are tracking how long patients live and how well the drug controls their cancer outside of a controlled clinical trial. …
Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Can a phone call help cancer survivors get the genetic answers they need?
Knowledge-focused CompletedThis study looked at whether offering genetic counseling by phone or video could help more childhood cancer survivors get genetic testing. About 391 survivors took part, comparing remote counseling to usual care. The goal was to see if remote services increase testing uptake and …
Sponsor: University of Chicago • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Hidden thyroid cancers: how common are they in patients with thyroiditis?
Knowledge-focused CompletedThis completed study from Minia University looked at 200 patients with autoimmune thyroiditis (an inflamed thyroid) who had thyroid surgery. The goal was to see how often thyroid cancer is found by accident when examining the removed tissue. Researchers checked for cancer in pati…
Sponsor: Minia University • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Your DNA may decide how well exercise and diet work for weight loss
Knowledge-focused CompletedThis study is testing whether a specific gene variant (MC4R rs17782313) and metabolic health status influence how men with obesity respond to a 12-week exercise and diet program. Forty men aged 18 to 59 with obesity will be classified as having metabolically healthy or unhealthy …
Sponsor: Harbin Sport University • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Cancer clot care under the microscope: new study mines data for better treatment insights
Knowledge-focused CompletedThis study reviews existing medical records to understand how blood clots (VTE) are treated in people with active cancer or a history of cancer. Researchers will look at which blood thinners are used, how often clots come back, and the costs involved. No new treatments are given—…
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
Protein shake vs. gut trouble: can whey help athletes digest fructose after heat stress?
Knowledge-focused CompletedThis pilot study tests whether a multi-ingredient whey supplement can reduce fructose malabsorption in healthy adults after hiking under heat stress. Eight participants will consume fructose and have their breath hydrogen measured as a marker of malabsorption, both before and aft…
Sponsor: Arizona State University • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
Can standard cancer treatment wake up the immune system? a study investigates.
Knowledge-focused CompletedThis study looks at how anti-tumor T-cell responses change in people with lung or head-and-neck cancer who are receiving radiochemotherapy. Researchers will collect blood and tumor samples to track immune markers. The goal is to understand whether this standard treatment can boos…
Sponsor: Centre Hospitalier Universitaire de Besancon • Aim: Knowledge-focused
Last updated Jul 25, 2026 00:00 UTC
-
Can a tumor-zapping procedure also wake up the immune system?
Knowledge-focused CompletedThis study looks at how two heat-based procedures — radiofrequency ablation and microwave ablation — affect the immune system in people with small liver cancers. Researchers will take blood samples and tissue biopsies before and after treatment to track changes in immune cells. T…
Sponsor: University Hospital, Grenoble • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
New catheter may sharpen radiation targeting in liver tumors
Knowledge-focused CompletedThis study compares two catheters used during the mapping step before radioembolization for liver cancer. One is a standard microcatheter, the other is a pressure-enabled device (TriNav). The goal is to see if the pressure-enabled catheter delivers more radioactive tracer directl…
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jul 22, 2026 00:00 UTC
-
ECMO in kids with cancer: a closer look at survival and risks
Knowledge-focused CompletedThis study examines how children under 18 with cancer or a history of a stem cell transplant do when they need a machine called ECMO to help them breathe. Researchers looked at bleeding, infections, and survival rates in children treated at one hospital, and compared survival wit…
Sponsor: Children's Mercy Hospital Kansas City • Aim: Knowledge-focused
Last updated Jul 22, 2026 00:00 UTC
-
Could your DNA predict thyroid cancer after radiation?
Knowledge-focused CompletedThis study investigates whether certain DNA variants make people more likely to develop thyroid cancer after receiving radiation therapy as a child. Researchers will compare the genetic profiles of about 30 people who developed thyroid cancer and 30 who did not, all of whom were …
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jul 22, 2026 00:00 UTC
-
Ultrasound inside the body reveals how tumors block the bile duct
Knowledge-focused CompletedThis study uses endoscopic ultrasound—a tiny ultrasound probe on a flexible tube passed through the mouth—to measure the size of the common bile duct in people with jaundice caused by pancreatic or bile duct tumors. Researchers aim to better understand how these tumors compress t…
Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Artificial intelligence could help guide liver cancer treatment after surgery
Knowledge-focused CompletedThis study developed an artificial intelligence model that analyzes MRI scans and pathology images to predict the risk of liver cancer returning after surgery. Researchers used data from over 500 patients who had their liver cancer surgically removed. The goal is to help doctors …
Sponsor: Anhui Provincial Hospital • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
New risk score aims to predict which pancreatic tumors will return after surgery
Knowledge-focused CompletedThis study aims to create a simple risk score to identify patients with pancreatic neuroendocrine tumors (PanNETs) who are at high risk of their cancer returning after surgery. Current methods are not very good at predicting individual risk. Researchers will analyze data from ove…
Sponsor: Fudan University • Aim: Knowledge-focused
Last updated Jul 12, 2026 00:00 UTC
-
Scientists mine 1,100 patient records to spot thyroid cancer return risks
Knowledge-focused CompletedThis study examines medical records from over 1,100 adults who had papillary thyroid cancer and were declared cancer-free after initial treatment. Researchers want to identify which patient characteristics—such as age, tumor size, or cancer spread—are linked to a higher chance of…
Sponsor: University of Roma La Sapienza • Aim: Knowledge-focused
Last updated Jul 12, 2026 00:00 UTC
-
AI model may personalize liver cancer care after surgery
Knowledge-focused CompletedThis study analyzed data from 1005 liver cancer patients to see who benefits from a treatment called TACE after surgery. Using machine learning, researchers aimed to predict individual patient outcomes. The goal is to help doctors decide whether to recommend TACE or just monitor …
Sponsor: Anhui Provincial Hospital • Aim: Knowledge-focused
Last updated Jul 11, 2026 00:00 UTC
-
Could your surroundings trigger a hidden genetic risk?
Knowledge-focused CompletedThis study investigates whether environmental and occupational exposures influence the risk of developing tumors in people who carry an SDHx gene mutation. Researchers will compare two groups of mutation carriers: those who have had a tumor and those who have not. The goal is to …
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
Could a smartphone replace clinic visits for rare tumor survivors?
Knowledge-focused CompletedThis study tests whether a remote monitoring program can reliably track the health of people who have had surgery for pheochromocytoma or paraganglioma (PPGL), rare adrenal tumors. Participants use an internet platform to report their data, which is compared to information collec…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
Blood scores may identify low-risk patients after hepatitis c cure, reducing need for lifelong cancer scans
Knowledge-focused CompletedThis study looks at whether simple, non-invasive blood test scores can predict the risk of developing liver cancer in people with advanced liver disease who have been cured of hepatitis C. Researchers analyzed data from 571 adults treated at a single hospital over ten years. The …
Sponsor: Siriraj Hospital • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC
-
PET-CT scans could sharpen radiation targeting for liver tumors
Knowledge-focused CompletedThis study investigates whether PET-CT scans can accurately measure the radiation dose delivered by radioactive spheres during a liver cancer treatment called radioembolization. Researchers will compare scans taken before and after the procedure in patients with liver tumors. The…
Sponsor: Fox Chase Cancer Center • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Decade-Long study aims to unlock liver disease risks in HIV-Hepatitis b patients
Knowledge-focused CompletedThis study follows adults in Zambia who have both HIV and chronic hepatitis B to track liver health over up to 10 years. Researchers aim to understand how current HIV treatments affect hepatitis B and liver damage, and to identify factors that lead to serious outcomes like liver …
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Radiation safety study aims to personalize thyroid cancer treatment
Knowledge-focused CompletedThis study collects standard-of-care images from people with differentiated thyroid cancer who are treated with radioactive iodine (Iodine-131). The goal is to better understand how much radiation reaches healthy organs and what dose is needed to destroy thyroid tissue. By gather…
Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Can a quick chat with a radiotherapy tech ease cancer patients' anxiety?
Knowledge-focused CompletedThis study looked at whether having a special consultation with a radiotherapy technician (called a manipulator) helps cancer patients feel more informed about their treatment. Researchers enrolled 308 adults with various cancers who were getting radiation therapy. They compared …
Sponsor: Centre Antoine Lacassagne • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Real-Time tissue test may help surgeons avoid unnecessary neck dissections in thyroid cancer
Knowledge-focused CompletedThis pilot study tested whether a rapid lab test called frozen section analysis, done during thyroid surgery, can help surgeons decide how many lymph nodes to remove from the neck. The study included 66 adults with low-risk thyroid cancer and no signs of spread before surgery. Th…
Sponsor: Eleonora Lori, MD • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New camera could make cancer treatment safer by better tracking radiation
Knowledge-focused CompletedThis study tested whether a new type of camera (VERITON-CT) can accurately measure radiation doses in patients receiving Lutathera, a treatment for certain cancers. Fifteen adults were scanned with both the new camera and a standard camera at different times after treatment. The …
Sponsor: Central Hospital, Nancy, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Lab study tests antibody that could unlock immune attack on liver cancer
Knowledge-focused CompletedThis completed study looked at a new antibody called anti-SIRPα as a potential immunotherapy for liver cancer. Researchers used blood and tissue samples from 30 liver cancer patients to see how the antibody affects immune cells. The goal was to understand whether blocking the SIR…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Study aims to cut hospital time after liver surgery by looking beyond medicine
Knowledge-focused CompletedThis completed study looked at 3000 patients having liver surgery to see if considering both medical and social factors could reduce how long they stay in the hospital. Researchers tracked things like complications and readmissions. The goal is to find ways to improve recovery an…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Can a Child's cancer be inherited? new study digs into family DNA
Knowledge-focused CompletedThis study looks at the DNA of 100 children (and young adults up to age 17) who have cancer, along with the DNA of their healthy parents. The goal is to find genetic changes that may have caused the cancer. By comparing the child's DNA to both parents', researchers hope to discov…
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Scientists explore GLUT1 protein as a diagnostic clue for rare lung tumors
Knowledge-focused CompletedThis study tested whether a protein called GLUT1 could help doctors better classify lung neuroendocrine tumors. Researchers analyzed tumor samples from 36 patients to see if GLUT1 staining patterns matched tumor type. The goal was to find a more reliable diagnostic tool than curr…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
German study reveals Real-World use of PRRT for neuroendocrine tumors
Knowledge-focused CompletedThis study looked at 117 people with gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) who received a type of radiation therapy called PRRT in German clinics. Researchers collected information on patient characteristics, treatment timing, and how PRRT was given in everyday…
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
PET scan patients may soon be allowed to move freely during the long wait
Knowledge-focused CompletedThis study tested whether letting patients move freely between the injection of a radioactive tracer and the PET scan affects image quality. Normally, patients must rest for an hour to avoid muscle uptake that can blur results. The trial involved 284 adults with cancer or needing…
Sponsor: Centre Hospitalier Régional d'Orléans • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Scientists probe Gut-Liver link in alcohol and fatty liver cancers
Knowledge-focused CompletedThis study looked at 180 people with liver cancer (hepatocellular carcinoma) who also had cirrhosis caused by either fatty liver disease or alcohol use. Researchers compared immune cells and gut bacteria in the liver to understand why cancer develops. The goal was to gather knowl…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can a quick GP visit improve cancer care? new study aims to find out
Knowledge-focused CompletedThis study looks at whether it's possible for people diagnosed with solid tumors to have a follow-up visit with their general practitioner within 15 days of learning their diagnosis. Researchers will track how many patients actually attend this visit and why some might not. The g…
Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Study aims to unlock secrets of immunotherapy skin reactions
Knowledge-focused CompletedThis study observed 255 cancer patients receiving immunotherapy to understand why some develop skin side effects. Researchers measured immune markers and lipids in the skin and blood. The goal is to identify patterns that could predict or explain these reactions.
Sponsor: National Jewish Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study tracks how CAR-T patients feel in real life
Knowledge-focused CompletedThis study looked at 170 patients with aggressive B-cell lymphoma who received CAR-T cell therapy. Researchers used surveys to track how patients felt about their fatigue, symptoms, and daily functioning over time. The goal was to understand the real-world impact of the treatment…
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:08 UTC
-
Zambia study tracks hepatitis b outcomes in hundreds of patients
Knowledge-focused CompletedThis study followed 326 adults in Zambia with chronic hepatitis B for up to 5 years. Researchers tracked how the virus behaves, how many patients need treatment, and how many develop serious liver problems like cirrhosis or liver cancer. The goal was to better understand the dise…
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Could a simple calculation replace a complex testosterone lab test?
Knowledge-focused CompletedThis study compared two methods for measuring bioavailable testosterone in the blood: the standard lab test (radioimmunoassay) and a mathematical calculation. Researchers included 270 men and women aged 18 to 90. The goal was to see if the calculation matches the lab test closely…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
HIV Patients' thyroid health under the microscope
Knowledge-focused CompletedThis study looked at how often thyroid problems (specifically an underactive thyroid) occur in people with HIV. Researchers reviewed medical records of 154 HIV-positive adults who were treated at a French hospital between 2001 and 2012. The goal was to get a clearer picture of th…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
New study reveals how brain scans predict surgery outcomes for pituitary tumors
Knowledge-focused CompletedThis study looked at 49 people with masses in the sellar region of the brain (near the pituitary gland). Researchers compared MRI scans before surgery with the final diagnosis after surgery to see how well imaging predicts the type of tumor. The goal was to improve diagnosis and …
Sponsor: Arab Board of Neurosurgery • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Study reveals why immunotherapy works differently in liver, lung, and brain tumors
Knowledge-focused CompletedThis study looked at medical records of 938 adults with solid tumors who received immunotherapy. Researchers compared how well the treatment worked when cancer had spread to different organs like the liver, brain, lung, or bone. The goal is to understand why some metastatic sites…
Sponsor: Wenlong Zhong, MD • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Proton therapy gets a daily Tune-Up in small pilot study
Knowledge-focused CompletedThis pilot study tested whether it's possible to adjust proton radiation plans each day while the patient is on the treatment table. Ten adults with solid tumors took part. The goal was to see if this approach is safe and practical enough to study in a larger trial.
Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Small study tests best way to mix chemo for liver tumors
Knowledge-focused CompletedThis study looked at 10 people with liver cancer (HCC) who were getting a standard treatment called chemoembolization (c-TACE). The goal was to see if mixing the chemotherapy drug doxorubicin with salt water or a contrast dye changes how the drug spreads inside the tumor. Researc…
Phase 4 • Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Smart scans and DNA tests could revolutionize liver cancer care
Knowledge-focused CompletedThis study looked at whether combining detailed MRI scans with whole genome sequencing can help doctors choose the best treatment for people with liver cancer. Researchers studied 200 adults who were scheduled for liver surgery. The goal was to see if these advanced tests provide…
Sponsor: Perspectum • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
New study aims to fix lack of diversity in cancer trials
Knowledge-focused CompletedThis completed study looked at ways to increase diversity in cancer clinical trials, focusing on breast, liver, and prostate cancers. Researchers worked with communities, doctors, and scientists in New York City to find better ways to include people of color and underserved group…
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
New website aims to close cancer care gap for black patients
Knowledge-focused CompletedThis study created and tested an educational website to help Black and African American cancer patients learn about personalized cancer treatments and clinical trials. Researchers interviewed 48 patients and caregivers, then tested the website with 33 patients. The goal was to se…
Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Blood tests and surveys may predict cancer treatment success
Knowledge-focused CompletedThis study followed 159 people with metastatic colorectal, pancreatic, biliary, or esophageal cancers who were starting a new line of therapy. Researchers collected blood samples (tumor markers and liquid biopsies) and patient-reported quality-of-life data to see if these could p…
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Thousands tracked in Largest-Ever liver cancer bead therapy registry
Knowledge-focused CompletedThis registry followed over 1,000 liver cancer patients who received SIR-Spheres—tiny radioactive beads injected into the liver's blood supply to kill tumors. The goal was to see how this treatment is used in real hospitals and how it affects survival, side effects, and quality o…
Sponsor: Cardiovascular and Interventional Radiological Society of Europe • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Brain radiation may erase personal memories, study warns
Knowledge-focused CompletedThis study looks at how radiation therapy for brain tumors like meningioma or pituitary adenoma might affect autobiographical memory—the memories of your life events. Researchers will ask 17 patients to complete memory tests one and two years after treatment. The goal is to see i…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
New ultrasound technique aims to better measure liver health
Knowledge-focused CompletedThis study tested a new ultrasound technique called ARFI to measure liver stiffness in 109 people, including healthy volunteers and patients with liver conditions. The goal was to understand normal stiffness values and how they change with disease or treatment. This is an observa…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Standing ultrasound spots hidden liver tumors better than lying down
Knowledge-focused CompletedThis study tested whether having patients stand during an ultrasound helps doctors see small liver tumors near the diaphragm that are often missed when lying down. Researchers scanned 95 people with confirmed liver lesions in three positions: standing, lying on their back, and ly…
Sponsor: The First Hospital of Jilin University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Anesthesia may alter gut bugs after liver surgery
Knowledge-focused CompletedThis study looked at how two different anesthesia methods (propofol vs. desflurane) affect gut bacteria and body chemistry in 60 adults undergoing liver tumor removal. Researchers measured changes in gut microbes and blood metabolites to see if anesthesia choice influences recove…
Sponsor: National Taiwan University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Cancer surgery recovery: quality of life under the microscope
Knowledge-focused CompletedThis study tracked 295 adults who had high-risk surgery for stomach, esophagus, pancreas, or liver cancer. Researchers measured quality of life before surgery and again at 6 and 12 months after. They also asked patients and their family members if they regretted the decision to h…
Sponsor: University Hospital, Geneva • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Hepatitis & liver cancer risk explored in immigrant communities
Knowledge-focused CompletedThis study tested 892 African and Asian immigrants for hepatitis B and C to understand how these infections raise the risk of liver cancer. Researchers also checked vaccination rates and tracked new cancer cases over time. No treatment was given; the goal was to gather informatio…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Tumor DNA test may match patients to smarter cancer drugs
Knowledge-focused CompletedThis study looked at whether analyzing the DNA of a patient's tumor can help doctors pick a targeted therapy for advanced or metastatic cancer. Researchers enrolled 550 adults with various solid tumors that had spread. They took biopsy or blood samples to search for genetic chang…
Sponsor: Institut Paoli-Calmettes • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Ultrasound vs. MRI: which is better for catching liver cancer early?
Knowledge-focused CompletedThis study looked at 211 people with liver cirrhosis to see which screening method works better for detecting liver cancer: an ultrasound every 6 months or an MRI once a year. Participants received both tests, and researchers measured how often each test correctly found cancer. T…
Sponsor: JOON-IL CHOI • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Liver scan may predict deadly failure after big operations
Knowledge-focused CompletedThis study tested whether a special liver scan (hepatobiliary scintigraphy) can predict liver failure in 326 patients undergoing major liver surgery. The scan measures how well the remaining liver works, which may be more useful than just measuring its size. If accurate, it could…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Thyroid cancer Drug's side effect on body mass measured in small study
Knowledge-focused CompletedThis completed study from the University of Pisa looked at how the thyroid cancer drug selpercatinib affects body composition. Fifteen adults on the drug had their lean mass and energy expenditure measured. The goal was simply to observe and gather data, not to test a new treatme…
Sponsor: University of Pisa • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Bile duct issues may shorten cancer treatment, study finds
Knowledge-focused CompletedThis study looked at medical records of 729 people in Japan with biliary tract cancer that could not be removed by surgery. Researchers wanted to see if bile duct problems during first treatment affected how long patients could stay on that treatment. The study did not test any n…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC
-
New biomarker may predict which cancer drugs work best
Knowledge-focused CompletedThis completed study tested whether a new biomarker called 'mass response' can predict how well a cancer therapy will work. Researchers collected tumor cells from 72 patients with various cancers through fluid drainage or biopsies. The goal was to see if this biomarker could guid…
Sponsor: Travera Inc • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
CAR-T therapy Follow-Up study shows no new safety surprises
Knowledge-focused CompletedThis study followed 16 people who had already received a special immune cell treatment (CLBR001 CAR-T) for various types of B-cell blood cancers like lymphoma and leukemia. The goal was to check for any new or long-term side effects that might appear months or years after treatme…
Phase 1 • Sponsor: Calibr, a division of Scripps Research • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Heart risk alert: troponin test may protect cancer patients on immunotherapy
Knowledge-focused CompletedThis completed study looked at 300 cancer patients treated with immune checkpoint inhibitors to see if measuring troponin levels could help detect serious heart problems early. The goal was to prevent major cardiovascular events like heart attack or stroke without unnecessarily s…
Sponsor: Institut Mutualiste Montsouris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Cancer drug heart risk mystery probed in new study
Knowledge-focused CompletedThis study looked at how immune checkpoint inhibitors, a type of cancer drug, might affect blood vessels and increase heart risks. Researchers measured blood vessel function and checked for related markers in 39 cancer patients before and after starting treatment. The goal was to…
Sponsor: Institut Mutualiste Montsouris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
New study tracks hidden heart and bone risks in Cushing's disease
Knowledge-focused CompletedThis study followed 80 people with newly diagnosed Cushing's disease for three years to see how the disease affects the heart, bones, metabolism, and quality of life. Researchers used blood tests, heart scans, bone density tests, and questionnaires to track complications before a…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
Pharmacist Check-Ups catch dangerous drug Mix-Ups in cancer care
Knowledge-focused CompletedThis study tested whether having a clinical pharmacist review medications for cancer patients before they start treatment could prevent drug-related problems. Researchers observed 440 adults with solid tumors who were about to receive chemotherapy, immunotherapy, or oral targeted…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Eye scan may forecast vision after brain surgery
Knowledge-focused CompletedThis study tested whether a type of eye scan called OCT-angiography can predict how well vision will recover after surgery to remove a pituitary tumor. Researchers compared the scan results with standard vision tests in 21 patients. The goal was to see if the scan could serve as …
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Cancer drug side effect under the microscope: muscle enzyme spike studied
Knowledge-focused CompletedThis study looked at how often a muscle enzyme called CPK increases in people with solid tumors who are taking a type of targeted therapy called tyrosine kinase inhibitors (TKIs). Researchers measured CPK levels in routine blood tests from 154 patients and checked if high levels …
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Simple test may spot frailty in elderly cancer patients
Knowledge-focused CompletedThis study looked at how common frailty is in people aged 70 and older with solid tumors who visited a cancer center. Researchers used a short questionnaire called VES-13 to screen patients before their doctor visit. They also compared the test results with the doctor's own judgm…
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Trial or standard care? study reveals emotional toll on cancer patients
Knowledge-focused CompletedThis study compared anxiety, depression, and quality of life between 125 cancer patients who joined clinical trials and those who received standard treatment. Researchers used questionnaires to measure stress and emotional well-being. The goal was to understand how trial particip…
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Real-world study reveals how well new liver cancer combo works in patients with cirrhosis
Knowledge-focused CompletedThis study looked at how safe and effective a combination of two drugs (Atezolizumab and Bevacizumab) is for people with liver cancer and cirrhosis, compared to standard pills (tyrosine kinase inhibitors). Researchers followed 38 patients to see how long they lived and how their …
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
New blood test spots silent spread of bile duct cancer before surgery
Knowledge-focused CompletedThis study tested whether a blood test that looks at tiny particles called exosomes can find cancer that has spread but is not visible on scans in people with a type of bile duct cancer (intrahepatic cholangiocarcinoma). The goal was to help doctors know who needs stronger treatm…
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
New study tackles bone pain caused by chemo-boosting drug
Knowledge-focused CompletedThis study watched 225 people with solid tumors who got a drug called G-CSF during chemotherapy. G-CSF can cause bone pain. Researchers measured pain levels and tracked what treatments (like pain relievers or other methods) helped. They also checked quality of life, fatigue, mood…
Sponsor: Ankara Etlik City Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
Simple frailty quiz may help predict chemo risks for seniors with stomach or bowel cancer
Knowledge-focused CompletedThis study looked at whether two simple frailty questionnaires (G8 and VES-13) can predict serious side effects from chemotherapy in people 65 and older with gastrointestinal cancers. Researchers followed 72 patients receiving standard chemotherapy and checked their frailty, nutr…
Sponsor: Ankara Etlik City Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
Rare tumor chemotherapy showdown: platinum vs. Non-Platinum
Knowledge-focused CompletedThis study analyzed data from 168 patients with a rare type of digestive neuroendocrine tumor (well-differentiated grade 3). Researchers compared survival and response rates in patients who received platinum-based chemotherapy versus those who received non-platinum chemotherapy. …
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
Tiny study tests if DNA can decide how much thyroid to remove
Knowledge-focused CompletedThis pilot study tested whether routine genetic analysis of thyroid cancer samples could help surgeons decide how much of the thyroid to remove. Only 2 patients were enrolled. The goal was to see if a larger trial is possible, not to change treatment yet.
Sponsor: University of California, Los Angeles • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
HIV Patients' CAR T-Cell cancer treatment under the microscope
Knowledge-focused CompletedThis study looked back at 30 people with HIV who received a special cancer treatment called CAR T-cell therapy for certain blood cancers. Researchers collected information from medical records to see what side effects occurred and how the immune system changed over time. The goal…
Sponsor: AIDS Malignancy Consortium • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
AI reveals gender differences in liver cancer spread risk
Knowledge-focused CompletedThis study looked at whether liver cancer spreads differently in men and women. Researchers analyzed data from over 19,000 patients and used computer models to create separate prediction tools for each gender. The goal was to better understand risk factors for cancer spread at th…
Sponsor: Tongji University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Urine test could replace repeated scans for adrenal tumors
Knowledge-focused CompletedThis study looked at 807 adults with adrenal tumors found by accident during scans for other reasons. Researchers compared the usual approach of repeat CT scans to a single urine steroid profile test to see which is more cost-effective for detecting cancer. The goal is to find a …
Sponsor: University Medical Center Groningen • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Simple frailty quiz may predict chemo risks in seniors
Knowledge-focused CompletedThis study looked at whether two easy-to-use frailty checklists (FRAIL and FiND) can predict severe side effects from chemotherapy in adults aged 65 and older with gastrointestinal cancers. Researchers followed 84 patients who had already had surgery and were receiving standard c…
Sponsor: Ankara Etlik City Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
New ventilation technique may make liver tumor procedures safer and more precise
Knowledge-focused CompletedThis study tested a new way of helping patients breathe during a procedure that destroys liver tumors with heat or electricity. The new method, called flow-controlled ventilation, keeps the diaphragm more still than standard methods, which could help doctors place needles more ac…
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Chemo nausea still a problem despite standard care, study finds
Knowledge-focused CompletedThis study tracked 300 cancer patients receiving their first round of chemotherapy to see how often nausea and vomiting still happen, even with standard anti-nausea medicines. Participants filled out questionnaires about their symptoms in the first 24 hours and up to 4 days after…
Sponsor: Centre Francois Baclesse • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
Scientists decode genetic secrets of liver cancer in 808 patients
Knowledge-focused CompletedThis completed study looked at the genetic makeup of liver cancer in 808 patients to better understand the disease. Researchers analyzed tumor samples from people treated with surgery, ablation, or transplant, as well as those with advanced cancer. The goal was to identify key ge…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Virtual reality test reveals hidden memory damage in cured Cushing's patients
Knowledge-focused CompletedThis study looked at whether people who have been cured of Cushing's disease for at least a year still have memory problems. Researchers used a special virtual reality test to check memory, along with standard tests. The goal was to better understand these lasting effects and imp…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
Can a simple spit test predict chemo-related deafness in kids?
Knowledge-focused CompletedThis study looked at 119 children who had platinum-based chemotherapy for certain cancers. Researchers wanted to find out if certain genes make some kids more likely to develop hearing loss from the treatment. By analyzing DNA from saliva samples, they hope to identify high-risk …
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
Mini-Tumor biobank could revolutionize cancer drug testing
Knowledge-focused CompletedThis completed study aimed to create a biobank of 'organoids'—tiny, 3D mini-tumors grown from liver cancer tissue. Researchers collected samples from 48 patients with colorectal cancer that spread to the liver or with primary liver cancer. The goal was to see if they could reliab…
Sponsor: Assistance Publique Hopitaux De Marseille • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Tumor marker may guide chemo choice for rare cancers
Knowledge-focused CompletedThis study looked at 116 people with advanced neuroendocrine tumors to see if a marker called MGMT can predict which chemotherapy works best. Researchers compared two chemo types—alkylating agents and oxaliplatin—based on MGMT status. The goal is to personalize treatment and impr…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Quick pause before liver surgery may shield organ from damage
Knowledge-focused CompletedThis study tested a technique called ischemic preconditioning (IPC) in 81 adults having major liver surgery. Before the main operation, surgeons briefly stopped blood flow to the liver to see if it would reduce liver injury. The goal was to lower liver enzyme levels after surgery…
Phase 3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
Imfinzi under the microscope: how does it perform outside the lab?
Knowledge-focused CompletedThis study tracked over 700 people in Korea who were already receiving the cancer drug Imfinzi (durvalumab) for lung or biliary tract cancer. The goal was to see how safe and effective the drug is in everyday medical practice, not just in strict clinical trials. Researchers monit…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
Liver health may change how lung cancer drug works
Knowledge-focused CompletedThis study looked at how the drug JDQ443 behaves in people with different levels of liver function. It included 33 adults with small cell lung cancer and mild, moderate, or severe liver problems, plus healthy volunteers. The goal was to measure drug levels in the blood to guide s…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC
-
Brazilian liver cancer study reveals Real-World treatment patterns
Knowledge-focused CompletedThis study reviewed medical records of 300 liver cancer patients treated in Brazil between 2017 and 2022. Researchers aimed to understand patient characteristics, how the cancer was managed, and survival outcomes. No new treatments were tested; instead, the goal was to gather rea…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
Scientists hunt for clues to predict liver cancer drug response
Knowledge-focused CompletedThis completed study analyzed tumor and blood samples from 166 people with advanced liver cancer who received a combination of atezolizumab and bevacizumab. The goal was to find biomarkers—biological clues—that could predict how well a patient responds to treatment and how long t…
Sponsor: CHA University • Aim: Knowledge-focused
Last updated Jun 26, 2026 14:13 UTC
-
Radioactive drug safety tracked for years in rare cancer patients
Knowledge-focused CompletedThis study follows 20 people with neuroendocrine tumors who previously received a radioactive drug called 177Lu-satoreotide tetraxetan. Researchers check for long-term side effects, including new cancers, every 3 months for up to 5 years. The goal is to understand the drug's safe…
Sponsor: Ariceum Therapeutics GmbH • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:29 UTC
-
Hidden cancer cells in lymph nodes may force second thyroid surgery in many patients
Knowledge-focused CompletedThis study looked at 314 patients with small, early-stage papillary thyroid cancer who had surgery to remove half of the thyroid. During the operation, doctors checked nearby lymph nodes for hidden cancer spread. If cancer was found, the rest of the thyroid was removed in the sam…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 26, 2026 12:45 UTC
-
Glowing dye helps surgeons see hidden liver tumors in real time
Knowledge-focused CompletedThis study tested whether a green dye called indocyanine green (ICG) combined with 4K cameras can help surgeons find liver tumors during keyhole surgery. 45 adults having liver surgery took part. The dye makes tumors and bile leaks glow under special cameras, which may help surge…
Sponsor: Klinikum Saarbrücken, Klinik für Allgemein-, Viszeral- und Thoraxchirurgie, Chirurgische Onkologie • Aim: Knowledge-focused
Last updated Jun 26, 2026 12:32 UTC